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Abstract
Glioblastoma (GBM) is an aggressive form of brain cancer that has a high recurrence rate
and very poor prognosis. The prognostic value of various molecular markers (e.g., IDH-1
mutation, MGMT promoter methylation, etc.) and clinical factors (e.g., age, KPS, surgery
and chemotherapy) has been studied in GBM after initial diagnosis but not as extensively
in the recurrent GBM. Utilizing a retrospective cohort design, based on quantitative data
collected through medical chart reviews, and the conceptual framework of outcomes
research in oncology, this study evaluated the prognostic value of IDH-1 mutation in
recurrent GBM in the context of key predictor variables of age, MGMT promoter
methylation, KPS, and surgery and chemotherapy at recurrence. The study specifically
evaluated if there was a significant difference in overall survival and progression free
survival between rGBM patients with and without IDH-1 mutation and if selected
molecular and clinical covariates affected these outcomes. The results of this study
indicated, albeit with its limitations, that IDH-1 mutation was not a prognostic factor in
recurrent GBM. The prognostic value of IDH-1 mutation from initial diagnosis in this
study was inconclusive, consistent with previous reports. The results of this study also
indicated that although methylated MGMT promoter was a strong prognostic factor from
initial diagnosis as previously reported, it was not a prognostic factor in recurrent GBM.
Overall, the results of this study suggest that the prognosis and treatment of GBM may
need to be considered differently at initial diagnosis and following disease recurrence. It
is anticipated that the results of this study will bring about a positive social change by
affecting both patient treatment and health care practice in recurrent GBM.
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Chapter 1: Introduction to the Study
Glioblastoma (GBM) is by far the most frequent malignant glioma. It is
associated with a particularly aggressive course and a dismal prognosis (Ostrom et al.,
2014). Glioblastoma is characterized by symptoms including slow progressive
neurological deficit, weakness in motor skills, headache, increased intracranial pressure,
and seizures (Ostrom et al., 2014). The tumor location may be indicated by these
neurological symptoms as well as by focal signs, including hemiparesis, sensory loss,
visual loss, and aphasia (Ostrom et al., 2014). Extremely rapid cell infiltration is a key
biological feature of glioblastoma; tumor cells travel to other sites within the brain, which
makes it very difficult to completely remove tumors through surgery (Olar & Aldape,
2014). Therefore, in conjunction with inadequate response to treatment, the recurrence
rate is very high with GBM, resulting in poor overall prognosis (Li et al., 2015). Newly
diagnosed GBM subjects have a median overall survival (mOS) of 12 to 15 months and a
2-year-overall survival (OS) rate of up to 27% (Omuro et al., 2013). Subjects who have
experienced multiple recurrences, referred to as recurrent GBM (rGBM), have a
particularly poor prognosis, with a mOS of 6 to 7 months. The OS in subjects who have
failed temozolomide (TMZ) and bevacizumab, or equivalent salvage chemotherapy, is as
short as 3 to 5 months (Iwamoto et al., 2009; Omuro & DeAngelis, 2013).
According to the National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) database, there are an estimated 166,039 people living with brain and
other nervous system cancers in the United States in 2015 (Cancer of the Brain and
Other Nervous System - Cancer Stat Facts, n.d.). The National Brain Tumor Society
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indicates that there are currently 700,000 Americans living with a brain tumor, of which
560,000 are benign and 140,000 are malignant (Quick Brain Tumor Facts, n.d.). Given
that gliomas comprise approximately 80% of all malignant brain tumors (Quick Brain
Tumor Facts, n.d.), the prevalence of malignant gliomas in the United States is
approximately 112,000. The 5-year survival rate for GBM is estimated at 5.6%; survival
decreases if the disease is diagnosed at an older age (Ostrom et al., 2018).
Glioblastoma is more common in older adults. The median age at diagnosis is 65
years and the incidence rate is highest in adults aged 75-84 years (Ostrom et al., 2018).
While the incidence rate is 1.6 times higher in males, the frequency of secondary GBM is
higher in females, with a male-to-female ratio of 0.65 (Ostrom et al., 2018; Thakkar et
al., 2014). The incidence rates of malignant brain and other central nervous system (CNS)
tumors are higher in Whites (7.62 per 100,000 persons) than Blacks (4.52 per 100,000
persons) and the incidence rate of GBM is approximately two times greater in Whites
than Blacks (Ostrom et al., 2018). There are no well-established environmental or
behavioral risk factors associated with brain or CNS tumors except exposure to ionizing
radiation (Ostrom et al., 2018); however, the risk of developing a brain cancer is twice as
high in individuals who have a parent, child, or full sibling diagnosed with brain cancer
(Ostrom et al., 2018).
Isocitrate dehydrogenase-1 (IDH-1) mutation status is now used in the
classification of gliomas, based on an understanding that IDH-1 mutant and wild-type
gliomas have different underlying tumor biology and therefore need to be treated
differently (Ostrom et al., 2018). A combination of radiotherapy (RT), chemotherapy, and
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surgical resection is typically used in the treatment of glioma patients. Clinical data have
showed benefits from the aggressive treatment of glioma patients with IDH-1 mutation,
making upfront and initial treatment with RT and chemotherapy a standard of care for
patients with IDH-1 mutant Grade II and III gliomas (Miller et al., 2017). Because the
role of IDH-1 mutation in rGBM is not well understood, it is difficult to determine
whether similar upfront aggressive treatment would confer any significant benefit to the
patients, given the risks associated with RT and chemotherapy. Hence, this study
specifically addressed this gap in research on the potential role of IDH-1 mutation in
rGBM, with the aim to improve disease prognosis and survival outcome in GBM and
rGBM patients. It is anticipated that the results of this study will help GBM patients and
their treating physicians make a more informed decision about the most appropriate
treatment regimen for managing the disease. After general background on GBM, this
chapter addresses the problem statement and purpose of the study along with specific
research questions. The conceptual framework of the study is briefly described followed
by study limitations, expected significance of the study, and overall chapter summary.
Background
Glioblastoma is an aggressive form of brain cancer that has very poor prognosis
(Ostrom et al., 2018). It is difficult to completely remove tumors through surgery, and the
cancer cells rapidly infiltrate other parts of the brain (Olar & Aldape, 2014); therefore,
GBM has a very high recurrence rate, which, in conjunction with inadequate response to
existing treatment, results in poor prognosis. The mOS for rGBM is 6-7 months; the mOS
for patients who have failed standard of care treatments is as short as 3 to 5 months
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(Iwamoto et al., 2009; Omuro & DeAngelis, 2013). IDH-1 mutation status is now used to
classify gliomas, based on the understanding that IDH-1 mutant and wild-type gliomas
have different underlying tumor biology and therefore need to be treated differently
(Miller et al., 2017).
Waitkus et al. (2016) provided a review of IDH mutations in gliomas, including
information about the biochemistry and effects of IDH mutations. They also highlighted
the utilization of IDH mutations as putative biomarkers for glioma, including its potential
role in disease prognosis and treatment outcomes (Waitkus et al., 2016).
Calvert et al. (2017) and Labussiere et al. (2010) underlined the role of IDH
mutation in GBM (Calvert et al., 2017; Labussiere et al., 2010). Calvert et al. highlighted
the upregulation of wild-type IDH-1/2 in GBM, while Labussiere et al. showed a fourfold longer survival among GBM patients with an IDH-1 mutation than among those with
wild-type IDH-1.
Amelot et al. (2015), Mukasa et al. (2012), and Zou et al. (2013) provided
different views of the controversy over the prognostic value of IDH mutation in GBM
(Amelot et al., 2015; Mukasa et al., 2012; Zou et al., 2013). For example, while Amelot
et al. identified IDH mutation as a weak prognostic factor for survival, Mukasa et al.
indicated that, at least in Grade III gliomas, IDH mutation was associated with long-term
survival. The meta-analysis conducted by Zou et al. also supported the prognostic value
of IDH mutation in GBM.
Taal, et al. (2014) and Mandel et al (2016) noted the paucity of knowledge about
the prognostic value of IDH-1 mutation in rGBM because limited studies have been
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conducted on this topic (Mandel et al., 2016; Taal et al., 2014). Moreover, the studies
conducted on rGBM included a total of only 10 patients with IDH-1 mutation, so they
indicated that the results of these studies must be interpreted with caution (Mandel et al.,
2016; Taal et al., 2014). Considering that the role of IDH-1 mutation as a prognostic
factor remains controversial, even at initial diagnosis, more studies are needed,
particularly in rGBM, to understand the role of IDH mutations in this disease.
Problem Statement
Glioblastoma is one of the most common types of malignant gliomas and has an
aggressive disease course and very poor prognosis (Ostrom et al., 2018). GBM may
manifest at any age, but it typically affects adults at age 45-84 (Ostrom et al., 2017;
Ostrom et al., 2014). IDH-1 gene mutation has been extensively studied as a prognostic
factor in GBM following initial diagnosis, but it has not been studied as much in rGBM
(Amelot et al., 2015; Mukasa et al., 2012; Ostrom et al., 2018). The prognostic value of
IDH-1 mutation is debated even following initial diagnosis of GBM: studies have
demonstrated both weak and strong association between IDH-1 mutation and overall
survival (Amelot et al., 2015; Mukasa et al., 2012; Zou et al., 2013). A few studies have
examined the role of IDH-1 mutation in rGBM, but only in the clinical trial setting and
with inconclusive results (Mandel et al., 2016; Taal et al., 2014). These studies suggest
that patients with IDH-1 mutated tumors show an improved trend in overall survival at
first recurrence; however, in rGBM trials, IDH-1 mutation did not result in prolonged
progression-free survival or overall survival compared to IDH-1 wild-type tumors
(Mandel et al., 2016). Moreover, studies conducted by Mandel et al. and Taal et al.
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included only a total of 10 patients (five patients in each study) with IDH-1 mutation. The
authors indicated that the results of these studies must be interpreted with caution, given
the very small sample size, and suggested additional studies be conducted to better
understand the role of IDH-1 mutation in rGBM (Mandel et al., 2016; Taal et al., 2014).
IDH-1 mutation status is now used in the classification of gliomas, given the
understanding that IDH-1 mutant and wild-type gliomas have different underlying tumor
biology and therefore need to be treated differently (Miller et al., 2017). A combination
of RT, chemotherapy, and surgical resection is typically used in the treatment of glioma
patients (Wick et al., 2018). Even though the long-term side effects of RT and
chemotherapy were initially questioned, particularly in low grade gliomas, over the years
clinical data has shown benefits from aggressive treatment of glioma patients with IDH-1
mutation (Czapski et al., 2018; Kazda et al., 2018; Paolillo et al., 2018; Zang et al.,
2018). This has made initial upfront treatment with RT and chemotherapy a standard of
care for patients with IDH-1 mutant Grade II and III gliomas (Miller et al., 2017).
Because the role of IDH-1 mutation in rGBM is not well understood, it is difficult to
determine whether similar upfront aggressive treatment would confer any significant
benefit to patients, considering the risks associated with RT and chemotherapy. This
study addressed this gap in research and evaluated the potential role of IDH-1 mutation in
rGBM, with an aim to improve disease prognosis and survival outcomes in rGBM
patients. It is anticipated that the results of this study will help rGBM patients and their
treating physicians make more informed decisions about the most appropriate treatment
regimen for managing the disease.

7
Purpose of the Study
The purpose of this study was to determine whether IDH-1 mutation is a
prognostic factor in rGBM considering other molecular and clinical prognostic factors as
covariates. In a retrospective cohort study, time to first recurrence from initial diagnosis
and time to disease progression or death from first recurrence was evaluated in GBM
patients with IDH-1 mutated and wild-type tumors. The effect of key variables (i.e., O-6methylguanine-DNA methyltransferase (MGMT) promoter methylation, age, Karnofsky
performance score (KPS), surgery for resection, and chemotherapy at progression) on
correlation between IDH-1 mutation status and disease progression and survival was also
evaluated. The study also estimated the overall prevalence of GBM as a type of nervous
system cancer at the participating hospitals in Massachusetts.
Research Questions and Hypotheses
RQ1: Is there a significant difference in time to disease progression and overall
survival after first recurrence between rGBM patients with IDH-1 mutation and those
without IDH-1 mutation?
H01: Based on IDH-1 mutation status, there is no statistically significant
difference in the time to disease progression and/or overall survival of rGBM patients.
H11: Based on IDH-1 mutation status, there is a statistically significant difference
in the time to disease progression and/or overall survival of rGBM patients.
RQ2: Is the correlation between IDH-1 mutation status and disease progression
and survival after first recurrence affected by the covariates of MGMT promoter
methylation, age, KPS, surgery for resection, and chemotherapy at progression?
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H02 – The correlation between IDH-1 mutation status and disease progression and
survival is not affected by covariates MGMT promoter methylation, age, KPS, surgery
for resection, and chemotherapy at progression.
H12 - The correlation between IDH-1 mutation status and disease progression and
survival is affected by covariates MGMT promoter methylation, age, KPS, surgery for
resection, and chemotherapy at progression.
Conceptual Framework for the Study
The aims and scope of the study were congruent with the conceptual framework
of outcomes research. The goal of outcomes research in oncology is to improve medical
practice in order to achieve better outcomes in patients (Lee et al., 2000). Outcomes
research draws on multiple specialties and subspecialties of clinical science to better
understand the effectiveness of treatments and to enable clinicians to make more
informed decisions (Lee et al., 2000). In oncology, outcome research addresses a broad
range of questions and oncology-related endpoints, such as overall survival (OS) and
progression-free survival (PFS), which are studied utilizing administrative databases and
cohort or case-control study designs (Lee et al., 2000). This conceptual framework is also
supported by other researchers, who are increasingly advocating that outcomes research
in oncology is more than health services research per se and that outcomes research
requires an integrated multidisciplinary approach in order to understand the complexity
of tumorigenesis and factors that impact patient outcomes (Apolone, 2003; Fay et al.,
2015; Kovvali, 2014; Melamed et al., 2017; Roberts et al., 2019). This study, from the
perspective of its research scope, methodology, and potential application, was within the
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parameters of research and applications of outcomes research (Lee et al., 2000). First, the
purpose of this study, to determine whether IDH-1 mutation is a prognostic factor in
rGBM, broadly fits the treatment options and prediction rules of the outcomes research
framework because IDH-1 mutation is an important prognostic factor that informs
treatment options. Second, the study utilized clinical outcomes like OS and PFS that are
suggested in the outcomes research framework (Lee et al., 2000). Furthermore, the
application aspect of the outcomes research conceptual framework suggests that the
research should lead to clinical or policy decisions (Lee et al., 2000). It is anticipated that
the results of this study will inform clinical decisions in terms of treatment
recommendations and clinical practice guidelines for the management of rGBM patients,
using IDH-1 mutation as a prognostic factor. The results of this study may also provide
some future directions for policy. For example, considering that the results of the study
indicate that aggressive treatments may not be necessary in rGBM, policy changes may
be made over time that could lead to substantial savings in the overall health care costs
associated with the management of this disease. Therefore, the overall scope of this study
– its research inquiry, methodology, and potential applicability – was contextualized
within the conceptual framework of outcomes research in oncology.
Nature of the Study
This study was a retrospective cohort study based on quantitative data collected
through retrospective chart reviews of adult patients diagnosed with GBM at select
hospitals in Massachusetts. An observational study design, rather than an experimental
design, was selected considering the scope of the study that aimed to evaluate the
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association between exposure (i.e., IDH-1 mutation) and disease outcome (i.e., time to
disease progression and overall survival) (Euser et al., 2009; Song & Chung, 2010).
Retrospective cohort design was selected mainly for efficiency because a prospective
cohort study would have been costly and time-consuming making it impractical for this
dissertation project. Individual chart reviews for patients provided data on initial
diagnosis and IDH-1 mutation status as well time to first recurrence, time to disease
progression or subsequent recurrence, and death. Disease outcomes – time to recurrence
from initial diagnosis, time to disease progression following first recurrence, and overall
survival – was evaluated to determine whether IDH-1 mutation is a prognostic factor for
adult GBM or rGBM patients. The Cox proportional-hazards model was used to assess
the effect (hazard ratio) of IDH-1 mutation status on time to disease progression and
survival. In addition, a Kaplan-Meir curve were generated to obtain the survival rate for
patients with and without the IDH-1 mutation. A Cox regression analysis was also
conducted to test the effects of other key covariates, including Karnofsky performance
score (KPS), surgery at the time of recurrence, and O-6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation status on progression and survival. The
prevalence of adult GBM was estimated based on the total number of adult brain cancers
diagnosed at the select hospitals during the same period as the study.
The study covered a duration of 12 years, from 2008 to 2020. To get an
estimate of the incidence and prevalence of GBM, the medical records at select
hospitals were searched for the total number of adult brain cancers and GBM patients
admitted and diagnosed at those centers during the specified time-period. The
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prevalence of GBM was estimated as a proportion of overall adult brain cancers
reported at the same centers during the specified time-period.
Retrospective medical chart reviews of patients with GBM or rGBM were
conducted to determine whether there is a significant difference in time to disease
progression or median overall survival. The key data that were collected from the chart
reviews included but not limited to: (a) patient demographics (e.g., age and gender), (b)
date of initial diagnosis of GBM, (c) standard treatment received at disease onset, (d)
IDH-1 phenotype and other genetic markers, (e) date of disease recurrence, (f) treatment
following disease recurrence, (g) time to disease progression following first recurrence,
and (h) date of death. Time to disease progression and overall survival for each patient
was calculated based on the date of disease onset or diagnosis and the date of disease
progression and death.
Definitions
Glioblastoma: A fast-growing central nervous system tumor that forms from glial
(supportive) tissue of the brain and spinal cord (Ostrom et al., 2014; Ostrom et al., 2018).
Recurrent glioblastoma: Glioblastoma typically returns or recurs after initial
treatment that may include chemotherapy and surgical removal (Apolone, 2003; Li et al.,
2015).
Overall survival: The duration or length of time that a patient is alive after initial
date of diagnosis of the disease or the start of treatment (Iwamoto et al., 2009; Omuro &
DeAngelis, 2013). In this study overall survival was assessed from the initial date of
diagnosis of the disease to death and date of first recurrence to death.
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Median overall survival: The duration or length of time that half of the patients in
a group of patients are alive after initial date of diagnosis of disease or the start of
treatment (Omuro & DeAngelis, 2013; Ostrom et al., 2014).
Time to disease progression or progression free survival: Time to disease
progression or progression free survival (PFS) is the duration or length of time after
initial treatment when patient goes in remission and recurrence or relapse of cancer
(Lamborn et al., 2008). In this study time to disease progression was considered as
duration of time to first recurrence from initial treatment and duration of time to second
recurrence from first recurrence.
Resection: Surgery performed to remove the tumor mass, which can be total or
partial resection depending on tumor location and access (Brown et al., 2016; Wilson et
al., 2014).
Prognostic factors: Patient characteristics or conditions that can provide some
estimation about the chance of recovery or recurrence of a disease in patients (Audureau
et al., 2018; Czapski et al., 2018; Goldman et al., 2018; Ostrom et al., 2018; Thakkar et
al., 2014). In this study molecular markers that is, IDH-1 mutation status and MGMT
promoter methylation status, and clinical factors like KPS, surgery for resection, and
chemotherapy at progression were evaluated as prognostic factors.
Assumptions
The study was a retrospective cohort study based on quantitative data collected
from electronic medical records (EMR) of adult patients diagnosed with GBM at select
hospitals in Massachusetts; therefore, the major assumption of this study was that the
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patient data in the EMR was collected and entered in a reliable and accurate manner,
particularly for the key variables. This assumption was supported by the robust processes
and standard operating procedures that each participating hospital have in place to ensure
data integrity. It would not have been feasible for the researcher to conduct an
independent audit of the data due to hospital policies, magnitude of the database, and
patient privacy concerns under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 (Rights (OCR), 2009). The other key assumption was the clinical
assessment of recurrence and disease progression in GBM patients. While radiographic
imaging was used as an objective measure to determine recurrence and progression of
disease, the assessment was nonetheless made by a clinician. GBM patients are under the
care of trained neurooncologists and such radiographical assessments are part of regular
clinical practice, including oncology.
Scope and Delimitations
The study specifically evaluated the role of IDH-1 mutation in recurrent GBM
because IDH-1 gene mutation has been extensively studied as a prognostic factor in
GBM following initial diagnosis, but it has not been studied as much in rGBM (Amelot et
al., 2015; Mandel et al., 2016; Ostrom et al., 2014; Ostrom et al., 2018; Thakkar et al.,
2014); therefore, only those GBM patients that have at least one confirmed diagnosis of
recurrence following initial diagnosis were included in the study whereas GBM patients
that do not have a confirmed diagnosis of recurrence were excluded from the study. The
study was designed as a retrospective cohort study based on quantitative data collected on
adult GBM patients at select hospitals in Massachusetts, including Brigham and
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Women’s Hospital and St. Vincent Hospital. These hospitals were selected to make the
research feasible through ease of collaboration with oncologists at these centers and
better access to EMR, which required the researcher to go through training at these
hospitals. This approach would not have been possible if too many cancer centers had
been selected, particularly ones in other states.
The study was conceptualized within the research component of the outcomes
research conceptual framework (Lee et al., 2000). It could be argued, however, that
Determinants of Health model (WHO | The Determinants of Health, n.d.) could have
been considered as the conceptual framework for this study. According to this model, the
health of an individual is affected by a combination of multiple factors or determinants,
and these determinants can be categorized into socioeconomic and physical environment,
and the person’s characteristics and behaviors (WHO | The Determinants of Health, n.d.).
Genetics and epigenetics, as a person’s individual characteristics, can play a role in the
development of an illness, including cancer, and affect the response to treatment
(Notterman & Mitchell, 2015). The model also entails, however, that multiple factors like
diet, environment, and biology may impact the genetic and epigenetic profile of an
individual (Mohammed et al., 2012). While the study investigated an epigenetic
biomarker, IDH-1 mutation, as a “determinant of health” in rGBM patients, it was
beyond the scope of this study to identify and account for all the factors that may lead to
this epigenetic phenotype and reasonably address the key research questions. Therefore,
outcomes research conceptual model was considered more appropriate for the scope of
this study and the research questions it aimed to address. The study directly tested the
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prediction rule (i.e., the prognostic value of IDH-1 in rGBM) using the outcomes (OS and
PFS) within the research component of the conceptual framework (Lee et al., 2000). The
results may provide future direction for the application component of the conceptual
framework, including both clinical practice and policy aspects, but further research would
be needed to validate the results of this study before such changes could be implemented.
Since the data collected for the study was limited to two hospitals in
Massachusetts and are not representative of the U.S. population, caution would need to be
taken in the generalizability of the results and conclusions. However, there is no evidence
to suggest that the pathophysiology and clinical course of GBM would be different across
the United States, and the data collected for this study had an appropriate distribution of
age, gender, and race/ethnicity variables consistent with the demographic data reported
for GBM (Ostrom et al., 2018). Furthermore, EMR provides detailed clinical data that is
relevant for outcomes research and is now increasingly used in clinical oncology and
epidemiology studies (Lau et al., 2011). Therefore, the risk of external validity was
considered minimal for this study.
Limitations
The key anticipated challenge and barrier for the study was access to GBM
patient medical records for retrospective chart review; however, collaborations were
established at select leading hospitals in Massachusetts, providing access to the data of
close to 1500 GBM patients. As anticipated, there were enough GBM patients in the
database to have a reasonable sample size for the study, the sample size was reduced once
the inclusion criteria of disease recurrence and IDH-1 mutation status, which was the key
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variable for the study, was applied. Clinical and molecular prognostic factors (e.g., age,
Karnofsky performance status (KPS), surgical resection, chemotherapy at progression,
and MGMT promoter methylation status) are considered key prognostic factors for
survival in recurrent GBM (Archavlis et al., 2014; Audureau et al., 2018; Chaichana et
al., 2013; Cloughesy et al., 2014; D’Amico et al., 2015; Ringel et al., 2016; Stupp et al.,
2012; Terasaki et al., 2007). Heterogeneity in these clinical and molecular prognostic
factors in the study population was also anticipated. Considering that the prognostic value
of the IDH-1 mutation for the rGBM patients in this study was determined by comparing
outcomes like time to disease progression and mortality, the confounding variables were
also factored in as covariates in the final data analysis. Cox regression analyses were
conducted to address this limitation and to evaluate the effect of these confounding
variables on the outcomes of interest. Analyses that matched the groups for these
covariates were not conducted due to the small sample size. Inability to match cohorts for
confounding variables is a general limitation and challenge that researchers face when
conducting research in a rare disease space, like GBM. In rare diseases, the sample size is
relatively small to begin with and patient heterogeneity makes it difficult to adjust for all
confounding variables while still maintaining a reasonable sample size for statistical
analysis.
Cohort studies may also be susceptible to selection, information, and comparison
bias (Euser et al., 2009). Inherent nature of the study that includes objective assessment
of exposure and outcome adequately addresses these potential biases. In terms of
selection bias, the inclusion of the GBM subjects in the study with the exposure of
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interest (IDH-1) mutation was not dependent on the likelihood of them having the
outcome of interest (disease progression and survival). Moreover, the diagnosis of GBM,
both initial and recurring, was based on radiographic assessment and therefore it
eliminated the selection bias due to differential referral or diagnosis (Euser et al., 2009).
Similarly, information bias due to misclassification was unlikely since presence or
absence of IDH-1 mutations is made by established laboratory diagnostic test.
Significance
This research study is significant from both epidemiological and patient care
perspectives. The results of the study, including demographics, genetic features, clinical
characteristics, prognoses, and outcomes, should provide insight to epidemiologists and
health professionals regarding the similarities and potential differences of this disease in
Massachusetts compared with national trends as reported in the literature. This study may
inform how best to identify, diagnose, and treat rGBM patients at the selected centers in
Massachusetts.
The presumed role of the IDH-1 mutation as an overall prognostic factor upon
initial diagnosis of GBM typically results in the selection of treatment modalities that are
relatively aggressive, including a combination of resection, chemotherapy, and adjuvant
therapy. In the absence of a clear understanding of the role of IDH-1 mutation status in
recurrent GBM, there is a gap in knowledge about whether such an aggressive treatment
approach in the recurrent setting would confer any added clinical or survival benefit to
patients over standard of care. Considering that there are significant risks associated with
aggressive treatments like craniotomy for resection, chemotherapy, and participation in
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clinical trials of investigational drugs, patients’ quality of life and an overall risk/benefit
profile need to be considered when selecting the optimal treatment course. The results of
this study are expected to contribute to positive social change by affecting both patient
management and health care delivery in rGBM. The results of this study indicate that
IDH-1 may not carry the same prognostic value after disease recurrence and treatment
decision that are made based on this marker at initial diagnosis may not be relevant or
accurate at disease recurrence. Considering that there are significant risks associated with
aggressive treatments like combination of chemotherapies that are selected based on
prognostic factors like IDH-1 mutation at initial diagnosis, the results of this study may
mitigate unnecessary exposure of rGBM patients to the safety risks that are associated
with such treatments. Similarly, if such treatments are not found necessary in the
recurrent setting, then positive social change may be affected over time as it could lead to
substantial savings in the overall health care costs associated with the management of this
disease.
Summary
Glioblastoma is by far the most frequent malignant glioma. It is associated with a
particularly aggressive course and a dismal prognosis (Ostrom et al., 2014). Extremely
rapid cell infiltration is a key biological feature of glioblastoma: Tumor cells travel to
other sites within the brain, which makes it very difficult to completely remove tumors
through surgery (Olar & Aldape, 2014). Therefore, in conjunction with inadequate
response to treatment, the recurrence rate is very high with GBM, resulting in poor
overall prognosis (Li et al., 2015). Subjects who have experienced multiple recurrences,
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referred to as recurrent GBM (rGBM), have a particularly poor prognosis, with a median
OS (mOS) of 6 to 7 months. The OS in subjects who have failed temozolomide (TMZ)
and bevacizumab, or equivalent salvage chemotherapy, is reported to be as short as 3 to 5
months (Iwamoto et al., 2009; Omuro & DeAngelis, 2013).
Isocitrate dehydrogenase-1 (IDH-1) mutation status is now used in the
classification of gliomas, based on an understanding that IDH-1 mutant and wild-type
gliomas have different underlying tumor biology and therefore need to be treated
differently (Ostrom et al., 2018). Clinical data have showed benefits from the aggressive
treatment of glioma patients with IDH-1 mutation, making upfront and initial treatment
with RT and chemotherapy a standard of care for patients with IDH-1 mutant Grade II
and III gliomas (Miller et al., 2017). However, the prognostic value of IDH-1 mutation in
GBM remains controversial (Amelot et al., 2015; Mukasa et al., 2012; Zou et al., 2013)
and limited studies have been conducted to evaluate the prognostic value of IDH-1 in
rGBM (Mandel et al., 2016; Taal et al., 2014). Because the role of IDH-1 mutation in
rGBM is not well understood, it is difficult to determine whether similar upfront
aggressive treatment would confer any significant benefit to the patients, given the risks
associated with RT and chemotherapy. Therefore, the purpose of this retrospective cohort
study was to determine whether IDH-1 is a prognostic factor in rGBM. The Cox
proportional-hazards model was used to assess the effect (hazard ratio) of IDH-1
mutation status on time to disease progression and survival. A multivariate Cox
proportional-hazard analysis was also conducted to evaluate if the correlation between
IDH-1 mutation status and disease progression and survival is affected by the covariates

20
of MGMT promoter methylation, age, KPS, surgery for resection, and chemotherapy at
progression. It is anticipated that the results of this study will help GBM patients, and
their treating physicians make more informed decisions about the most appropriate
treatment regimen for managing the disease, particularly in the recurrent setting. Chapter
2 provides additional background on the disease and the current understanding on the
most relevant molecular and clinical prognostic factors in GBM/rGBM—it therefore
provides the foundation for the study hypotheses and rationale for the selection of key
variables and covariates of the study.
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Chapter 2: Literature Review
Glioblastoma (GBM) is one of the most common types of malignant gliomas. It
has an aggressive disease course and very poor prognosis. GBM may manifest at any age,
but it typically affects adults at age 45-84 (Ostrom et al., 2018). Isocitrate dehydrogenase1 (IDH-1) gene mutation has been extensively studied as a prognostic factor in GBM
following initial diagnosis, but it has not been thoroughly studied in recurrent GBM
(rGBM). Even following initial diagnosis of GBM, the prognostic value of IDH-1
mutation has been debated, as studies have demonstrated both weak and strong
association between IDH-1 mutation and overall survival (Amelot et al., 2015; Mukasa et
al., 2012; Zou et al., 2013). A few studies have examined the role of IDH-1 mutation in
rGBM, but only in the clinical trial setting and with inconclusive results (Mandel et al.,
2016; Taal et al., 2014).
The purpose of this study was to determine whether IDH-1 mutation is a
prognostic factor in rGBM. In this retrospective cohort study, time to first recurrence
from initial diagnosis and time to disease progression or death from first recurrence was
evaluated in GBM patients with IDH-1 mutated and wild-type tumors.
This literature review contextualizes the research study by focusing on topics and
publications related to the construct and variables of interest. The key variable of interest
for the research study is IDH-1 gene mutation status and its value as a prognostic factor
in the overall survival of rGBM patients. Therefore, the review first focuses on molecular
classification of GBM to highlight some important genetic markers, like IDH-1, that have
been identified in GBM and their potential role in the disease pathophysiology. The
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review then focuses on the current knowledge base on prognostic factors, both clinical
and molecular, in GBM and rGBM. These reviews of the molecular classification of the
disease and prognostic factors provide the rationale for selecting IDH-1 mutation status
as the key variable of the study, as well as the important molecular and clinical covariates
that need to be considered when evaluating the association between IDH-1 mutation and
overall survival in rGBM patients. Finally, a review of current treatment provides insight
on how prognostic factors can inform treatment decisions. This review is relevant in the
context of the social change that this study is anticipated to make in terms of the
management of rGBM patients. There is a dearth of studies that have specifically focused
on molecular and clinical prognostic factors in rGBM. However, the rationale for
hypothesizing a role for various prognostic factors in rGBM can be derived from the
existing research on GBM in general and rGBM in particular.
Literature Search Strategy
Pub-Med, Medline, Society of Neuro-Oncology publications, and Walden
University Library were the primary sources for the literature search, which mainly
focused on peer-reviewed journal articles. Key search terms included glioblastoma,
recurrent glioblastoma, IDH mutation in glioblastoma, IDH mutation in recurrent
glioblastoma, prognostic factors in glioblastoma, prognostic factors in recurrent
glioblastoma, prognostic factors in glioblastoma meta-analysis, treatment of
glioblastoma and recurrent glioblastoma, risk factors in glioblastoma, IDH mutation as
prognostic factor in glioblastoma, IDH mutation as prognostic factor in recurrent
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glioblastoma, conceptual framework in cancer and oncology, and outcomes research in
oncology.
Considering the rapidly evolving research and knowledge about GBM, articles
published over the last 3 to 5 years (2014 to 2020) were preferred for information on key
variables of interest (e.g., IDH, molecular markers, and prognostic factors in GBM and
rGBM). Earlier publications were considered for providing general background on GBM,
foundational research, and conceptual framework. The search term meta-analysis was
included for key variables like IDH mutation in GBM and prognostic factors in GBM.
Conceptual Framework
The aims and scope of the proposed study are congruent with the conceptual
framework of outcomes research, particularly outcomes research in oncology, the goal of
which is to improve medical practice to achieve better outcomes in patients (Lee et al.,
2000). The definition of outcomes research and what it encompasses has evolved since
the mid-1960s, particularly in the field of oncology, with the realization that the
emergence of tumors and tumorigenesis are complex phenomena involving genetic,
epigenetic, metabolic, proteomic, and physiologic pathways (Kovvali, 2014). While the
definition of outcomes research will continue to evolve, it is broadly understood as a field
that describes, interprets, and predicts the influence of different factors on a final
endpoint that may range from survival to patient satisfaction with care (Apolone, 2003).
In 1966 Avidence Donabedian used the term “outcome” in the context of quality
of medical care, with a focus on health services and care provided according to the
expected standards (Lee et al., 2000). Advances in technology brought an increase in
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healthcare costs and the focus of outcomes research shifted to health care costs (Lee et
al., 2000). For example, in 1973 John Wennberg and Alan Gittelsohn highlighted
different patterns and variations in care in terms of resource utilization and costs (Lee et
al., 2000). In the 1990s, however, outcomes research began to include more specialties
and subspecialties of clinical science in order to better understand the effectiveness of
treatments and to enable clinicians to make more informed decisions (Lee et al., 2000). In
the mid-1990s, a distinction between outcomes research and health services research
began to emerge. Along with new technologies, therapeutic interventions, and clinical
trials, the definition of clinical research also encompassed epidemiologic studies,
outcomes research, and health services research (Nathan, 1998). Outcomes research
began to address a broad range of questions and oncology-related endpoints, like overall
survival (OS) and progression-free survival (PFS), which were studied utilizing
administrative databases and cohort or case-control study designs (Lee et al., 2000).
Lee et al. (2000) included a diagrammatic representation of the conceptual
framework of outcomes research, which is reproduced as Figure 1.
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Figure 1
Conceptual Framework for Outcomes Research

Note: Lee et al. (2000, p. 200) (see Appendix for copyright permission).
As indicated in Figure 1, Lee et al. (2000) suggested that clinical trials are not part
of outcomes research, whereas quality of care, access, decision making, prediction rules,
and effectiveness, along with outcome endpoints, are considered part of outcomes
research. Lee et al. suggested that studies that use administrative databases are typically
considered outcomes studies regardless of the questions they seek to address. Similarly,
while endpoints like OS and PFS are also included in clinical trials, these endpoints are
considered part of outcomes research when they are used in cohort studies with
administrative databases (Lee et al., 2000). While Lee et al. acknowledged that the term
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outcomes research has been liberally used and the nomenclature will continue to evolve,
this study adopts their conclusion that “outcomes research is fundamentally concerned
with improving the practice of medicine as applied to patients treated outside clinical
trials” (Lee et al., 2000 p. 203)
The view of Lee et al. (2006) seems to be corroborated by other researchers, who
are increasingly arguing that outcomes research in oncology is more than health services
research per se and that outcomes research itself requires an integrated multidisciplinary
approach in order to understand the complexity of tumorigenesis and the factors that
impact patient outcomes (Apolone, 2003; Fay et al., 2015; Kovvali, 2014; Melamed et
al., 2017; Roberts et al., 2019). For example, drawing upon systems biology, Kovvali
(2014) has proposed the term systems oncology, suggesting that the disease should be
studied as a phenomenon from the perspective of multiple areas of research like
molecular biology and immunology. Melamed et al. (2017) suggested that randomized
clinical trials may not be feasible in gynecologic oncology, thus outcomes research based
on well-designed observation studies can provide better guidance on clinical decisions.
Similar views were expressed by Fay et al. (2015) with respect to GBM. They indicated
that an integrated multidisciplinary research approach is needed to better understand this
cancer and improve patient outcomes because GBM treatment practices have not
significantly changed over the past 10 years.
This study is aligned with the conceptual framework of outcomes research,
particularly outcomes research in oncology as proposed by Lee et al. (2000) and
generally adopted by other researchers (Apolone, 2003; Fay et al., 2015; Kovvali, 2014;
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Melamed et al., 2017; Roberts et al., 2019). The study’s research scope, methodology,
and potential application fall within the parameters of research and applications of
outcomes research that Lee et al. outlined and illustrated in the conceptual framework
(see Figure 1). First, the purpose of this study was to determine whether IDH-1 mutation
is a prognostic factor in rGBM by evaluating time to first recurrence from initial
diagnosis and time to disease progression or death (overall survival) from first recurrence
in GBM patients with IDH-1 mutated and wild-type tumors. This broadly fits the
treatment options and prediction rules of the outcomes research framework. In GBM,
IDH-1 mutation is an important prognostic factor that informs treatment options, and this
study evaluated the role of this mutation in the recurrent setting. Second, the study
utilized clinical outcomes, OS and PFS, that are suggested in the outcomes research
framework. Third, the study was a retrospective cohort study and analyses were based on
data obtained from electronic medical records (EMR) at select hospitals. EMR provides
detailed clinical data that are relevant for outcomes research and is now increasingly used
in clinical oncology and epidemiology studies (Lau et al., 2011). Moreover, Lee et al.
(2006) suggested that studies that use administrative databases and study these endpoints
are typically considered outcomes studies regardless of the questions they seek to
address. Finally, the application aspect of the outcomes research conceptual framework
suggests that the research should lead to clinical or policy decisions (Lee et al., 2000).
The results of this study may inform clinical decisions in terms of treatment
recommendations and clinical practice guidelines for the management of rGBM patients,
using IDH-1 mutation as a prognostic factor. The results of this study indicate that IDH-1
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mutation is not a prognostic factor in the recurrent setting and an aggressive treatment
approach will most likely not confer any clinical or survival advantage over standard of
care; therefore, the results of this study may mitigate the unnecessary exposure of patients
to the risks associated with such procedures and treatments. Similarly, if such treatments
are not found necessary in the recurrent setting, then policy changes may be made over
time that could lead to substantial savings in the overall health care costs associated with
the management of this disease. Therefore, the overall scope of this study, in terms of its
research inquiry, methodology, and potential applicability, was contextualized within the
conceptual framework of outcomes research in oncology.
Literature Related to Key Variables
Molecular Characterization of Glioblastoma
A review of the molecular classification of GBM highlights some important
genetic markers, like IDH-1, that have been identified in GBM and their potential role in
the disease’s pathophysiology. Glioblastoma is morphologically or histologically divided
into two identical subtypes: primary and secondary glioblastoma (Lieberman, 2017; Olar
& Aldape, 2014). Primary glioblastoma occurs de novo without the presence of a
precursor lesion and constitutes approximately 90% of GBM (Lieberman, 2017; Olar &
Aldape, 2014). Secondary glioblastoma follows the progression of WHO Grades II or III
with preexisting low-grade astrocytoma (Lieberman, 2017; Olar & Aldape, 2014).
Recent advances in molecular neuropathology have shown that molecular
characterization can be utilized to further classify glioblastomas that are histologically
identical (Lieberman, 2017; Olar & Aldape, 2014). Moreover, even though these
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molecular alterations are complex, this genetic profiling has suggested there is prognostic
value in these molecular variations and therefore a possible association with clinical
outcomes of GBM. The following is a brief outline of the key genetic alterations in GBM
that are considered clinically relevant (Lieberman, 2017; Olar & Aldape, 2014).
Isocitrate Dehydrogenase (IDH) Mutation
IDH has three isoforms, the most common of which includes mutation in IDH-1
(IDH1-R132H) (Lieberman, 2017; Olar & Aldape, 2014). IDH mutations are noted in
approximately 5% of primary GBM and 80% of secondary GBM (Lieberman, 2017; Olar
& Aldape, 2014). IDH-1 mutation has been associated with better prognosis, particularly
in high-grade gliomas (Lieberman, 2017; Olar & Aldape, 2014). In 2016, IDH mutation
status was included in the WHO classification of GBM. Currently, GBM is classified as a
WHO Grade IV tumor of the central nervous system and is divided into three subtypes
based on histology and molecular parameters: IDH-wildtype, IDH-mutant, and not
otherwise specified (Louis et al., 2016). The Cancer Genome Atlas (TCGA) researcher
network has suggested that other genetic abnormalities may also be clinically relevant
(Verhaak et al., 2010).
Epidermal Growth Factor Receptor (EGFR)
Upregulation of EGFR has been reported in 40-50% of glioblastomas,
predominantly in primary glioblastomas but also in secondary glioblastomas (Lieberman,
2017; Olar & Aldape, 2014). EGFR, including its mutant variants like EGFRvIII, has
been shown to confer heterogeneity to tumor cells and upon activation leads to
angiogenesis, DNA transcription, cell proliferation, and delayed apoptosis (Lieberman,

30
2017; Olar & Aldape, 2014). The effects of EGFR upregulation in GBM and rGBM are
not clearly understood.
O-6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation
MGMT encodes a DNA repair protein that is responsible for removing alkyl
groups that cause DNA damage (Olar & Aldape, 2014; Yang et al., 2015). The MGMT
promoter contains CpG islands in the promoter region, and methylation of these CpG
sites suppresses MGMT transcription (this is called MGMT silencing), thereby affecting
DNA repair (Olar & Aldape, 2014; Yang et al., 2015). Based on this underlying
molecular biology, methylation status of the MGMT promoter is associated with a more
favorable response to alkylating chemotherapies, like temozolomide (TMZ). Over 50% of
primary and secondary GBM patients have methylated MGMT promoter (Olar & Aldape,
2014; Yang et al., 2015). While MGMT promoter methylation status is now considered a
prognostic factor in patients with GBM, its prognostic value in rGBM is not fully
established (Olar & Aldape, 2014; Yang et al., 2015).
TP53 Mutation
TP53 mutation has been reported in up to 30% of primary and 70% of secondary
GBM patients (Thakkar et al., 2014). The prognostic value of TP53 mutation has not
been established and studies conducted to evaluate it as a prognostic marker have been
inconclusive (Thakkar et al., 2014).
ATRX Mutation
ATRX mutations result in genomic instability by causing alternative lengthening
of telomerases (ALT). They have been noted in multiple tumors (Thakkar et al., 2014).
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The ATRX is mutated in 57% of secondary GBM patients and tends to cluster with IDH1 and TP53 mutations (Thakkar et al., 2014). In astrocytic tumors, better prognosis has
been reported for patients with ATRX mutation than in those that expressed unmutated
ATRX and had IDH mutation (Thakkar et al., 2014).
TERT Mutation
TERT is important for growing cells and maintains telomeres. TERT mutations
are the most frequently occurring genetic mutations in GBM and are significantly higher
in primary GBM (Thakkar et al., 2014). While TERT mutations in GBM have been
shown to correlate with EGFR upregulation, they have been shown to inversely correlate
with TP53 and IDH mutations (Thakkar et al., 2014).
Prognostic Factors
This review of prognostic factors first covers GBM in general and then rGBM in
particular. The intent is to provide background information that supports the investigation
of IDH-1 mutation status as a potential prognostic factor in rGBM. The review of other
clinical and molecular markers provides a rationale for the selection of appropriate
covariates in the overall analysis.
Prognostic Factors in GBM
GBM patients have very poor prognosis: a 5-year survival after diagnosis is seen
in less than 5% of patients (Ostrom et al., 2018; Thakkar et al., 2014). Research has
focused on both clinical and molecular prognostic factors (Ostrom et al., 2018; Thakkar
et al., 2014). Age at diagnosis, tumor location, performance status, and tumor resection
have been identified as favorable clinical prognostic factors, while the key molecular
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markers discussed above (MGMT promoter methylation, IDH-1 mutation, EGFR
upregulation, TP53 mutation, ATRX mutation, and TERT mutations) have been studied
as potential molecular prognostic factors in GBM (Ostrom et al., 2018; Thakkar et al.,
2014).
Clinical Prognostic Factors. Age 50 years is typically used as the cut-off from a
prognostic value perspective, with a higher risk of death seen in patients over 70 years.
The shorter survival rate for older GBM patients is most likely due to comorbidities and
inability to tolerate the effects of the cancer itself and treatments like surgery and
chemotherapy (Ostrom et al., 2018; Thakkar et al., 2014). In terms of tumor site, while
the difference in the prognosis of cerebellar and supratentorial GBM is not clearly
understood, frontal lobe tumors in supratentorial GBMs have better prognosis and
survival outcomes (Ostrom et al., 2018; Thakkar et al., 2014).
Surgical treatment includes complete macroscopic tumor removal or gross total
resection (GTR) and subtotal resection (Czapski et al., 2018). While resection is an
important treatment option in GBM, it does not offer a cure and is not completely
effective due to the unclear boundary between tumor and healthy brain tissues and the
infiltration of tumor cells into surrounding areas (Czapski et al., 2018). Even with this
limitation, GTR has been shown to increase survival to up to 20 months in malignant
gliomas, compared to 8.8 months with no GTR (Czapski et al., 2018). Lu et al. (2019)
conducted a meta-analysis to look at the survival benefit of maximal resection for
glioblastoma and reported that radiographic GTR was the most prognostic in terms of
survival (HR 0.52; 95% CI, 0.44-0.61; p < 0.01) (Lu et al., 2019). Intraoperative MR
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imaging, ultrasonography, and tumor staining are now utilized to better define the tumor
boundaries and maximize resection (Czapski et al., 2018). Recent studies, however, have
highlighted the timing of resection and its association with PFS and OS in GBM
(Goldman et al., 2018; Y.-H. Zhao et al., 2019). For example, a lower risk of death (HR:
0.62) was noted with repeat resection without taking the timing of resection into account,
but a higher risk of death was noted (HR: 2.19) after adjustment for the timing of
resection (Goldman et al., 2018). An association has also been noted between tumor
resection and IDH mutation, as patients with IDH-mutated tumors showed better
prognosis following maximal tumor resection (Czapski et al., 2018).
Molecular Markers as Prognostic Factors. Several molecular prognostic
markers have been investigated in GBM and their interactions are complex (XavierMagalhães et al., 2013). The prior section provided a brief outline of the key molecular
markers in GBM. This subsection focuses on the two markers, MGMT promoter
methylation and IDH-1 mutation, that are considered the most promising in terms of their
prognostic value and that have been extensively studied for this purpose.
MGMT Promoter Methylation. As discussed earlier, silencing of MGMT by
promoter methylation suppresses MGMT transcription (MGMT silencing), thereby
affecting DNA repair (Olar & Aldape, 2014; Yang et al., 2015). Two landmark studies
showed that MGMT silencing leads to increased sensitivity to chemotherapy with
temozolomide, thereby improving patient survival (Hegi et al., 2005; Stupp et al., 2009).
Hegi et al. (2005) showed that mOS in patients with methylated MGMT was 21.7
months, compared to 12.7 months in patients with unmethylated MGMT. Similarly, in
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Stupp et al. (2009), longer survival was noted in patients with MGMT promoter
methylation. These patients also responded better to a combination of radiotherapy (RT)
and chemotherapy. These two studies provided initial evidence for MGMT promoter
methylation as a prognostic molecular marker in GBM.
Several studies have been conducted over the last 10 years to further evaluate the
role of MGMT promoter methylation as a prognostic factor in GBM. This body of work
has been captured in three meta-analyses (Olson et al., 2011; H. Zhao et al., 2016; Y.-H.
Zhao et al., 2018). Olson et al. (2011) was based on 2018 patients in 20 different studies
and showed a high association between MGMT promoter methylation and overall
survival in patients receiving chemotherapy (Olson, 2011). Similarly, both H. Zhao et al.
(2016) and Y.-H. Zhou et al. (2018) indicated that MGMT promoter methylation was
associated with improved PFS and OS in GBM patients. For example, Y.-H. Zhao et al.
included 64 studies and evaluated the association between OS and MGMT promoter
methylation in GBM patients. The meta-analysis showed that the OS was significantly
better (HR = 0.52) in patients with methylated MGMT promoter than in patients with
unmethylated status (Y.-H. Zhao et al., 2018). Overall, these studies suggest a prognostic
value for MGMT promoter methylation in GBM patients (Olson et al., 2011; H. Zhao et
al., 2016; Y.-H. Zhao et al., 2018). There are, however, other studies that did not show a
statistical significance between MGMT promoter methylation and survival (Costa et al.,
2010; van den Bent et al., 2009; Xavier-Magalhães et al., 2013). For example, Costa et al.
(2010) included 90 GBM patients who received post-operative TMZ; while a trend was
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noted in MGMT promoter methylation and PFS and OS, it was not statistically
significant (Costa et al., 2010).
IDH Mutations. IDH-1, IDH-2, and IDH-3 are three different isoforms of IDH.
Mutations in IDH-1 and IDH-2 have been identified in both hematologic and solid
tumors, including low-grade gliomas and secondary glioblastomas (Golub et al., 2019;
Kaminska et al., 2019; Tommasini-Ghelfi et al., 2019). IDH-1 mutation is the most
common (> 95%) type of IDH mutation, while an association between tumors and IDH-3
mutation has not been reported (Deng et al., 2018; Golub et al., 2019; Kaminska et al.,
2019). IDH-1 and -2 are nicotinamide adenine dinucleotide phosphate (NADP+)dependent enzymes that are involved in the decarboxylation of isocitrate to αketoglutarate (α-KG) and protect cells and DNA from being damaged by reactive oxygen
species (ROS) and other oxidative stress (Kaminska et al., 2019). The mutated IDH
enzyme not only loses the aforementioned catalytic function, but also leads to reduction
of α-KG to 2-hydroxyglutarate (2-HG), which is an oncometabolite that causes cancer
(Kaminska et al., 2019).
Approximately 90% of GBM cases are IDH-wild type and are known as primary
GBM, while the 10% of cases that carry IDH mutation, predominantly IDH-1 mutation,
are considered secondary GBM (Tateishi et al., 2017; Tommasini-Ghelfi et al., 2019).
Over the years, many studies have established IDH-1 mutation as a favorable prognostic
factor for both PFS and OS in adult GBM (Chen et al., 2016; Cheng et al., 2013; Juratli et
al., 2012; Kaminska et al., 2019; Nobusawa et al., 2009; Sun et al., 2013; Tateishi et al.,
2017; Xia et al., 2015; Yan et al., 2009). For example, Chen et al. (2016) conducted a
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meta-analysis that included randomized controlled trials and prospective and
retrospective studies of patients with GBM; it used PFS and OS to evaluate the
association between IDH mutation and prognosis. The pooled hazard ratios of 0.322
(95% CI 0.24200.455, P < .001) and 0.358 (95% CI 0.264-0.487, P < .001) indicated that
IDH mutation was associated with PFS and OS, respectively (Chen, 2016). Similarly, Xi
et al. (2015) performed a meta-analysis of 55 observational studies, including 9,487
glioma patients, and found that patients with IDH mutation had a better prognosis in
terms of both PFS (HR = 0.42, 95% CI: 0.35-0.51; P < .001) and OS (HR = 0.39, 95%CI:
0.34-0.45; P < .001). An earlier meta-analysis by Cheng et al. (2013) that included ninestudies, with a total of 1,669 GBM patients, also confirmed that IDH-1 mutation was
associated with improved survival in patients with GBM (HR = 0.45, 95%CI 0.29-0.69, P
< .001). Some studies, however, do not support an association between IDH-1 mutation
and long-term survival in GBM and indicate that IDH mutation is a weak predictor of
overall survival in GBM (Amelot et al., 2015; Mukasa et al., 2012). For example, Amelot
et al. (2015) conducted a retrospective analysis of 207 GBM patients and reported that
the rate of IDH mutation was not statistically significant between non-long-term survivor
and long-term survivor groups (1.16% versus 5.9%, p = .14).
Some underlying mechanisms by which IDH-1 mutation may confer survival
benefit to GBM patients include: (a) while the IDH-1 mutation plays a role in causing
cancer, it also makes cells carrying this mutation susceptible to ROS-based
chemotherapies; (b) tumors with IDH-1 mutation seem to be located in less risky parts of
the brain and have sharper tumor margins, making them more amenable to complete
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resection, which plays an important role in survival; and (c) patients with IDH-1 mutated
tumors typically display better neurocognitive function and overall performance score
(Tateishi et al., 2017).
Prognostic Factors in Recurrent GBM
Identifying factors that can predict survival outcomes following recurrence of
GBM is of interest because these factors can inform treatment modalities for such
patients. Age, Karnofsky performance status (KPS), surgical resection, and chemotherapy
at progression have been identified as key clinical prognostic factors for survival in
recurrent GBM (Archavlis et al., 2014; Audureau et al., 2018; Chaichana et al., 2013;
Cloughesy et al., 2014; D’Amico et al., 2015; Ringel et al., 2016; Stupp et al., 2012;
Terasaki et al., 2007). However, the complexity of disease pathophysiology and
interactions between molecular and clinical markers of prognosis make it challenging to
conclusively determine the most appropriate prognostic factors in GBM, including
rGBM. For example, while Audureau et al. (2018), in their study of 777 adult patients
with recurrent glioblastoma, identified surgical resection at recurrence as an independent
predictor of long-term survival (HR, 0.57; 95% CI 0.44-0.73; p < .001), their findings are
confounded by the exclusion of IDH mutation status and MGMT promoter methylation
status, which are independent predictors of overall survival, at least in GBM. Moreover,
while several studies have established surgical resection as a predictor of overall survival
in rGBM (Audureau et al., 2018; Chaichana et al., 2013; D’Amico et al., 2015), other
studies have suggested that surgery at progression may not be a prognostic marker for
survival outcomes in rGBM patients. For example, Clarke et al. (2011) studied two
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independent data sets of 511 and 247 rGBM patients and found no statistically significant
difference in 6-month PFS or OS between patients with and without surgery at
progression (Clarke et al., 2011). Despite these discrepancies, age, KPS, surgical
resection, and chemotherapy at progression should be considered as important prognostic
factors in rGBM and factored in as covariates when investigating any other specific
prognostic factors.
Molecular markers like IDH-1 gene mutation have been extensively studied as
prognostic factors in GBM, but not in the recurrent setting. Even following initial
diagnosis of GBM, the prognostic value of IDH-1 mutation is being debated in view of
studies that have demonstrated both weak and strong association between IDH-1
mutation and overall survival (Amelot et al., 2015; Mukasa et al., 2012). A few studies
have examined the role of IDH-1 mutation in rGBM, but only in the clinical trial setting
and the results were not conclusive (Mandel et al., 2016; Taal et al., 2014). These studies
suggested that patients with an IDH-1 mutated tumor show an improved trend in overall
survival at first recurrence. However, IDH-1 mutation did not result in prolonged PFS or
OS compared to IDH-1 wild-type tumors in recurrent GBM trials (Mandel et al., 2016).
Moreover, studies conducted by Mandel (2016) and Taal (2014) included a total of only
10 patients (five patients in each study) with IDH-1 mutation. The authors indicated that
the results of these studies must be interpreted with caution, considering the very small
sample size, and suggested additional studies to better understand the role of IDH-1
mutation in rGBM.
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Current Therapies and Unmet Medical Need
Newly diagnosed GBM subjects have a median overall survival (mOS) of 12 to
15 months and a 2-year OS rate of up to 27% (Omuro & DeAngelis, 2013). Subjects who
have experienced multiple recurrences have a poor prognosis, with an mOS of 6 to 7
months; OS in subjects who have failed TMZ and bevacizumab, or equivalent salvage
chemotherapy, is reported to be as short as 3 to 5 months (Iwamoto et al., 2009; Omuro &
DeAngelis, 2013). The poor median OS rates in rGBM, resulting from the available
treatment options not extending the subjects’ OS beyond 6 or 7 months, highlights the
seriousness of recurrent or progressive GBM as well as the unmet medical need in
treating this disease.
The current FDA-approved therapies – bevacizumab, carmustine wafer,
NovoTTF-100A, and lomustine – are marginally effective in extending OS in subjects
with recurrent or progressive GBM (Davis, 2016). Despite the scientific advances in
immunotherapies and monoclonal antibodies, a new standard of care for GBM has not
been established in over 10 years. TMZ following RT is still the standard of care and it
was established in 2005 following a Phase 3 trial that was led by Roger Stupp and
sponsored by the European Organization for Research and Treatment of Cancer and the
NCI - Clinical Trials Group (Davis, 2016; Stupp et al., 2009). The lack of standard
salvage therapies has prompted the use of unsatisfactory treatment options, such as
nitrosoureas, temozolomide re-challenge, and other targeted agents (Davis, 2016). In
addition to surgical resection and approved therapies, a better understanding of tumor
microenvironment and the potential role of immune regulation and epigenetic pathways
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in disease pathophysiology has led to the initiation of clinical trials with various immune
modulators, including monoclonal antibodies, vaccines, PD-1/PDL-1 checkpoint
inhibitors, and DNA methyltransferase inhibitors (Artene et al., 2018; Chin et al., 2018;
Jain, 2018; Paolillo et al., 2018; Zhang et al., 2019). These therapies, if proven effective
and safe either as monotherapies or in combination, can provide additional treatment
options for GBM patients.
Summary of Research Approach in Literature
GBM is considered to be of the most aggressive and untreatable forms of cancer
(Paolillo et al., 2018). The topics of research in GBM aimed at understanding the
pathophysiology of the disease and meeting the needs of patients through more effective
treatments are expansive and rapidly evolving. On the one hand, researchers are focusing
on molecular, genetic, epigenetic, and immunological markers in GBM, not only to better
classify the disease but also to evaluate the prognostic value of these markers in terms of
disease outcomes. On the other hand, researchers are also evaluating the role of clinical
prognostic factors, such as age at diagnosis, tumor site, surgical resection, and its timing,
KPS, and chemotherapeutic regimens, in the disease outcome. However, there are
complex interactions between these molecular and clinical prognostic factors and
researchers are aware that they need to adjust for other potential prognostic factors, both
molecular and clinical, when evaluating the role of any specific factor for its prognostic
value. This study took similar considerations into account in its design.
Apart from some prospective clinical trials conducted for novel therapies
targeting underlying genetic, epigenetic, and immunological markers in disease

41
pathophysiology, most of the research conducted in this space has been retrospective.
Because these retrospective studies are typically single- or limited-center studies, similar
patient molecular and clinical information is available to make reasonable comparisons
for the variables of interest. Furthermore, the number of such retrospective studies
conducted over the years has created a database that is adequate for more in-depth
analysis, as indicated by meta-analyses that have evaluated the prognostic value of
MGMT promoter methylation status, IDH mutation status, and surgical resection for the
long-term survival of GBM patients. However, there are some general limitations to
conducting GBM research, which are further accentuated in retrospective studies
conducted at limited centers. First, GBM is a rare disease with just over 100,000 patients
in the United States; this affects the sample size and design of the studies conducted.
Second, the GBM patient population is very heterogenous in terms of the genetic,
epigenetic, and immunological markers that they express and the treatment modalities
that they receive in the course of their disease (e.g., surgical resections and the timings of
these resections, chemotherapies, and immunotherapies). This overall heterogeneity,
along with the rareness of the disease and the small sample size, makes it difficult to
completely match the groups in a comparative study on the variable of interest.
Summary and Conclusions
The body of knowledge on rGBM, including studies evaluating its prognostic
factors, is less extensive than on GBM overall. While it is reasonable to draw inferences
from the results of studies that evaluated prognostic factors for GBM, the prognostic
value of these molecular and clinical factors needs to be evaluated in the recurrent setting
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as well to inform the most suitable treatment course for GBM patients following
recurrence. This literature review has indicated that for rGBM researchers have focused
more on clinical prognostic factors like tumor location and timing of surgical resection
than on molecular prognostic factors. A few studies have explored the prognostic value of
molecular markers like IDH mutation in rGBM, but the sample size was too small to
draw any reasonable conclusions. Considering that there is still some debate about the
prognostic value of factors like MGMT promoter methylation and IDH mutation even in
GBM, further studies are warranted that specifically evaluate the prognostic value of such
factors in rGBM.
The focus of this research study was to evaluate the prognostic value of IDH-1
mutation status in rGBM. Because GBM is not curable, all patients relapse: disease
recurs at some point following remission after initial treatment. While the overall
knowledge of clinical and molecular prognostic factors in GBM also informs
treatment-modalities selected for patients at recurrence, a better understanding of the
relevance of these prognostic factors in the recurrent setting may provide further insight
into treatment decisions for rGBM patients. For example, understanding the role of IDH1 in rGBM is relevant because over the years clinical data has shown a benefit from the
aggressive treatment of glioma patients with IDH-1 mutation, thereby making upfront
and initial treatment with RT and chemotherapy a standard of care for patients with IDH1 mutant gliomas (Miller et al., 2017). Because the role of IDH-1 mutation in rGBM is
not well understood, it is difficult to determine whether similar aggressive treatment at
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recurrence will confer any significant benefit to the patients, given the potential risks
associated with RT and chemotherapy.
Other relevant molecular and clinical prognostic factors need to be considered as
covariates in investigating the prognostic value of IDH-1 in rGBM. This literature review
suggests that MGMT promoter methylation (molecular marker), age, KPS, surgery for
resection, and chemotherapy at progression (clinical factors) would be important
covariates when comparing the PFS and OS of rGBM patients with and without IDH-1
mutation.
Consistent with other studies conducted to determine the association between
prognostic factors and clinical outcomes like PFS and OS, this study was a retrospective
cohort study based on quantitative data collected through retrospective chart reviews of
adult patients diagnosed with GBM at select hospitals in Massachusetts. Individual chart
reviews for patients provided data on initial diagnosis and IDH-1 mutation status as well
time to first recurrence, time to disease progression or subsequent recurrence, and death.
Disease outcomes – time to recurrence from initial diagnosis, time to disease progression
following first recurrence, and overall survival – was evaluated to determine whether
IDH-1 mutation is a prognostic factor for adult rGBM patients. The Cox proportionalhazard model was used to assess the effect (hazard ratio) of IDH-1 mutation status on
time to disease progression and survival. In addition, a Kaplan-Meir curves were
generated to obtain survival rate for patients with and without IDH-1 mutation. Cox
regression analysis was also conducted to test the effects of other key covariates –
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MGMT promoter methylation, age, KPS, surgery for resection, and chemotherapy at
progression–on progression and survival.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine whether isocitrate dehydrogenase-1
(IDH-1) mutation is a prognostic factor in recurrent glioblastoma (rGBM) considering
other molecular and clinical prognostic factors as covariates. In a retrospective cohort
study, time to first recurrence from initial diagnosis and time to disease progression or
death from first recurrence was evaluated in GBM patients with IDH-1 mutated and wildtype tumors. The effect of key variables (i.e., O6-methylguanine-DNA methyl-transferase
(MGMT) promoter methylation, age, Karnofsky Performance Score (KPS), surgery for
resection, and chemotherapy at progression) on correlation between IDH-1 mutation
status and disease progression and survival was evaluated. The study also determined the
overall prevalence of GBM as a type of nervous system cancers reported at select centers
in Massachusetts.
This chapter provides an overview of the research design and rationale to address
specific research questions pertaining to potential prognostic role of IDH-1 mutation in
disease progression and overall survival of rGBM patients as well the effects of other
covariates on prognostic effect of IDH-1 mutation. The population and sampling sections
describe the population of GBM patients that was included in the study and the inclusion
criteria that was used to include subject specific data in the overall evaluable sample from
the retrospective cohort. The data analysis plan section describes how each research
question was addressed based on the key study variables utilizing appropriate statistical
methods and quantitative analysis with IBM SPSS Statistics (version 25) software
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obtained through Walden University. Chapter also covers aspects of external and internal
validity based on the overall scope of the study and its design and limitations. A brief
overview of ethical considerations is included before the overall summary of this chapter.
Research Design and Rationale
Study Variables
In a retrospective cohort study design, relevant data on GBM patients was
collected at two selected Massachusetts hospitals (i.e., Brigham and Women’s and St.
Vincent Hospitals). Table 1 outlines the patient-level independent and dependent
variables that were selected to address specific research questions. The status of IDH-1
mutation was the key independent variable and was categorized as a nominal variable.
Key dependent variables were time-to-disease progression and survival. These dependent
variables were categorized as interval variables (i.e., number of days) and were measured
from initial diagnosis of GBM in each subject as well from first and/or subsequent
recurrences in the same subject. In addition to demographic information, independent
variables included key covariates selected for the study including MGMT promoter
methylation, age, KPS, surgery for resection, and chemotherapy a progression.
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Table 1
Dataset Variables
Variable

Coding Description

Level of Measurement

Independent Variables (Exposure Variable)
IDH-1 mutation status

Yes = 1; No = 2

Nominal

Gender

Female = 1; Male = 2

Nominal

Age

> 18 and <55 = 1; 56-65 =
2;

Nominal

66-75 = 3; >76 = 4
Ethnicity

Black = 1; White = 2;

Nominal

Hispanic = 3; Asian = 3
Other/Unknown = 4
Hospital

BWH* = 1; SVH** = 2

Nominal

MGMT promoter
methylation

Yes = 1; No = 2

Nominal

Missing data = 3
Karnofsky Performance
Score (KPS)

>70 = 1; <70 =2

Nominal

Missing data = 3
Surgery for resection

Yes = 1; No = 2

Nominal

Chemotherapy at
recurrence

Yes = 1; No = 2

Nominal

Dependent Variables (Outcome Variable)
Time to disease
progression or first
recurrence from initial
diagnosis

Number of days

Interval
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Variable

Coding Description

Level of Measurement

Time to subsequent
recurrence from first
recurrence

Number of days

Interval

Time to death from initial
diagnosis

Number of days

Interval

Time to death from first
recurrence

Number of days

Interval

*BWH = Brigham and Women’s Hospital.
**SVH = St. Vincent Hospital.
The two hospitals included in this study represented two major centers, one each
in the Eastern (BWH) and Western (SVH) part of Massachusetts. There are other
hospitals in the region that refer GBM patients to BWH. The retrospective analysis
timeframe for this study included a period of 12 years from January 2008 to 2020.
Study Design
This study was a retrospective cohort study based on quantitative data collected
through retrospective chart reviews of adult patients diagnosed with GBM at select
hospitals in Massachusetts. An observational study design, rather than an experimental
design, was selected considering the scope of the study that aimed to evaluate the
association between exposure (i.e., IDH-1 mutation) and disease outcome (i.e., time to
disease progression or progression free survival and survival) (Euser et al., 2009; Song &
Chung, 2010). Study cohorts, in terms of exposure, and outcome measures are
summarized below.
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Exposure and Cohorts
IDH-1 gene mutation in tumors of GBM patients was considered as the exposure
of interest for the purposes of this study; therefore, the two cohorts were defined based on
this exposure status that is, GBM patients that had IDH-1 mutation and GBM patients
without IDH-1 mutation or wild-type IDH-1 gene. In GBM, testing for IDH-1 mutation
status is done utilizing sensitive diagnostic tests at the time of the initial diagnosis of the
disease and the result of this testing is included in the medical records along with other
clinical and diagnostic assessments conducted as part of the initial diagnosis. In this
study, the date of exposure (IDH-1 mutation status) for each patient in each cohort was
the same as the date of their initial diagnosis of GBM as this testing was conducted per
the standard practices as part of the initial diagnosis and the information was available
during the initial chart review; therefore, for the purposes of this study the exposure in
each patient in each cohort occurred before the outcomes described below.
Study Outcomes
Time to disease progression or progression free survival (PFS) and survival were
the two main outcomes selected for this study. PFS was considered as the duration of
time from initial diagnosis and treatment of disease to first recurrence and duration of
time from first recurrence to subsequent recurrence or disease progression. Survival was
considered as either the duration of time from initial diagnosis of the disease to death or
duration of time from first recurrence of disease to death. In this study, time in days was
calculated to determine PFS and survival in patients with and without mutated IDH-1
gene. In addition to the date of initial diagnosis, the medical record of each patient
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included a date, along with a documented imaging evidence, of disease recurrence that
allowed to determine the duration of time from initial diagnosis to first and subsequent
recurrences. Similarly, the date of death was also recorded in the medical records that
allowed to determine the survival duration from initial diagnosis and from first disease
recurrence. As noted above, the date of the IDH-1 mutation status (exposure) was
considered the same as the date of initial diagnosis as this information was available in
the records for each patient at initial diagnosis. The events of disease progression and
death, that respectively determined the outcomes of PFS and survival, happened after the
initial diagnosis of disease and determination of IDH-1 mutation status; therefore, the
exposure in each patient in each cohort occurred before the selected study outcomes.
Individual chart reviews for patients provided data on initial diagnosis and IDH-1
mutation status as well time to first recurrence, time to disease progression or subsequent
recurrence, and death. Disease outcomes – time to recurrence from initial diagnosis, time
to disease progression following first recurrence, and overall survival – were evaluated to
determine whether IDH-1 mutation is a prognostic factor for adult GBM and rGBM
patients. Retrospective cohort design was selected mainly for efficiency because a
prospective cohort study would have been costly and time-consuming making it
impractical for this dissertation project. Moreover, the proposed study was aligned with
the conceptual framework of outcomes research, particularly outcomes research in
oncology that has been generally adopted by researchers (Apolone, 2003; Fay et al.,
2015; Kovvali, 2014; Lee et al., 2000; Melamed et al., 2017; Roberts et al., 2019).
Outcomes research addresses a broad range of questions and oncology-related endpoints,
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like overall survival (OS) and progression-free survival (PFS), which are now being
studied utilizing administrative databases and cohort or case-control study designs
(Apolone, 2003; Fay et al., 2015; Kovvali, 2014; Lee et al., 2000). The study utilized
clinical outcomes, OS and PFS, that are suggested in the outcomes research framework
and were based on data obtained from electronic medical records (EMR) at select
hospitals. EMR provides detailed clinical data that are relevant for outcomes research and
is now increasingly used in clinical oncology and epidemiology studies (Lau et al., 2011).

Methodology
Population
The target population consisted of subjects with confirmed diagnosis of GBM in
the EMR database of the two hospitals in Massachusetts. Some subjects obtained their
initial diagnosis of GBM at other hospitals in the region and were referred to these
hospitals for treatment. The databases were searched through a Research Patient Data
Repository (RPDR) query using the International Classification of Disease-10 (ICD-10)
code. Since GBM or rGBM does not have a specific ICD-10 code, initial search was
conducted using the ICD-10 code C71 for “malignant neoplasm of the brain.” As
anticipated the search based on ICD-10 code C71 resulted in approximately 1200-1500
cases that included all neoplasms of the brain. It was not feasible to review individual
patient records of all these cases to identify patients that would qualify for evaluable
population (i.e., subjects included in the analysis plan) to determine the prognostic value
of IDH-1 mutation; therefore, to make the database search manageable, the strategy
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outlined below in sampling and sampling procedure was used instead to identify
evaluable study population based on the key variables of the study that is, IDH-1
mutation status and GBM patients with documented recurrence of their disease.
Sampling and Sampling Procedures
This study was based on secondary analysis through retrospective chart review of
quantitative data collected on adult subjects with GBM at select hospitals in
Massachusetts. Since it was not possible to review the 1200 to 1500 cases that resulted
from suing the ICD-10 code C71 for “malignant neoplasm of the brain”, the database
search strategy was revised to identify relevant cases based on the key variables of the
study that is, IDH-1 mutation status and GBM patients with documented recurrence of
their disease. The database was first queried for all patients who had been tested for IDH1 mutation and this search yielded a total of 588 cases. Since IDH-1 mutation can be of
interest in a variety of oncologic conditions (e.g., myeloid leukemia, breast cancer, and
lung cancer) (Bledea et al., 2019; Hodges et al., 2013), the ICD-10 code C71 for
neoplasm of the brain was then applied to these 588 cases to further narrow the cases to
relevant study population and this step reduced the sample size to 405 cases. In the final
step, individual patient records for all 405 cases were reviewed and per the
inclusion/exclusion criteria those patients that had non-glioblastoma tumors, or did not
have confirmed diagnosis of GBM through radiographic imaging, or GBM patients with
no documented evidence of recurrence were excluded from the final dataset. This
strategy resulted in a final sample size of 177 cases, whose charts were then reviewed in
detail to collect all relevant information for detailed analyses to address the research
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questions. Each subject’s protected health information, except for demographic
information, was de-identified and all relevant data was entered on an Excel spreadsheet
and cross-checked against the EMR generated output for accuracy. These data were then
uploaded from the Excel spreadsheet into SPSS v25 for analysis.
An a priori analysis conducted using G*Power3 indicated that a sample size of
108 subjects was needed to detect a small effect size (d = .15) at an expected power of .90
and an alpha of .05 (Faul et al., 2007). The sample size was also estimated using the
method proposed by Hsieh and Lavori (2000) that provides a conservative sample size
estimation specifically for Cox proportional hazard regression model (Hsieh & Lavori,
2000). Although the inclusion criteria restricting the study sample to only rGBM patients
with known IDH-1 mutation status narrowed the overall study population, the final
sample size (177 cases) still exceeded the sample size of 108 that was estimated a priori
using G*Power3 (Faul et al., 2007).
Data Collection
The study was designed as a retrospective cohort study. A major step in the data
collection process was the selection of participating hospitals to ensure that enough
relevant and reliable data was available for GBM patients to address the research
questions and the relative ease with which this data could be accessed for the study.
Initial assessment was done by interviewing neuro oncologists within my professional
network to determine the number of GBM cases seen or referred to select hospitals in the
areas, the availability of medical records for these patients, interest in collaboration on
the study, and the flexibility in the institutional process to allow access to these data for
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collaborating researchers. Brigham and Women’s Hospital (BWH) and St. Vincent
Hospital (SVH) were selected for this study because it was anticipated that there were
approximately 1500 hundred subjects with neoplasms of the brain in the combined
databases that could provide required sample size per the inclusion/exclusion criteria of
the study particularly key variables of the study that is, patients with known IDH-1
mutation status and document evidence of recurrent GBM. Furthermore, both hospitals
have a robust EMR system in place for patient medical records that could be searched
and retrieved for required information. BWH and SVH are key hospitals, respectively, in
the Eastern and Western part of Massachusetts and GBM patients from other hospitals in
the region are also referred to BWH. Dr. Timothy Smith, Director, Computational
Neuroscience Outcomes Center and Assistant Professor of Neurosurgery, Brigham and
Women’s Hospital and Harvard Medical School and Dr. Daniyal Siddiqui, Chief,
Division of Hematology and Medical Oncology, St. Vincent Hospital agreed to
collaborate on the study. A brief outline of the research study was submitted to both
collaborating oncologists and these clinicians facilitated institutional/IRB approval.
Ability to access patient level data, as a researcher not employed at the hospital,
was also an important factor in selecting BWH and SVH as participating hospitals in this
study. The EMR data at BWH was accessed as part of an already approved broader GBM
research protocol under the supervision of collaborating and principal investigator, Dr.
Timothy Smith. Dr. Smith included me in his research team, and I completed all BWH
required training prior to the start of data collection. Similarly, Dr. Daniyal Siddiqui
obtained necessary approval from SVH hospital and included me in his team as a
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collaborating researcher. Once appropriate approvals from Walden University were
obtained, including IRB approval, data collection step was initiated for the study. The
BWH and SVH’s institution policy allowed me to view the EMR, but I was not able to
query the data since only employed medical personnel are given EMR log-in information.
I created the data query based on the inclusion criteria and study variables of interest and
queried the EMR for the required datasets in collaboration with and under the supervision
of Dr. Smith and Dr. Siddiqui’s designated residents on the team. Confidentiality of the
retrieved EMR data was maintained by ensuring that the data were not disclosed to any
unauthorized user at any time and any data that were not properly de-identified was held
with Drs. Smith and Siddiqui at the hospital with limited access by only authorized
individuals on their team. Once the data were retrieved, each subject’s protected private
health information, except for demographic information, was de-identified. The deidentified data were then entered on an Excel spreadsheet and cross-checked against the
EMR generated output for accuracy. The de-identified data was downloaded from the
Excel spreadsheet into SPSS v25 for analysis.
Electronic medical records provide detailed clinical data that is relevant for
outcomes research and is now increasingly used in clinical oncology and epidemiology
studies (Lau et al., 2011). It was assumed for purposes of this study that patient data in
the EMR was collected and entered in a reliable and accurate manner since both
participating hospitals follow robust processes and standard operating procedures to
ensure data integrity. It was not feasible to conduct an independent audit of the data due
to hospital policies, magnitude of the database, and patient privacy concerns under the
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Health Insurance Portability and Accountability Act (HIPAA) of 1996 (Rights (OCR),
2009) . Similarly, GBM patients are under the care of trained neuro oncologists;
therefore, it was assumed that the medical information they entered about their patients in
the EMR was accurate because of their extensive training in the medical practice of neuro
oncology.
Data Analysis Plan
Data analysis was conducted using the SPSS v25 obtained through Walden
University. Data in SPSS was directly uploaded from an Excel spreadsheet and manual
check was performed to ensure accuracy of data transfer. The data analysis addressed the
following study specific research questions and hypothesis. These research questions
along with key variables, their level of measurement, and statistical methods that were
used to address each question are outlined in Table 2.
RQ1: Is there a significant difference in time to disease progression and overall
survival after first recurrence between rGBM patients with IDH-1 mutation and those
without IDH-1 mutation?
H01: Based on IDH-1 mutation status, there is no statistically significant
difference in the time to disease progression and/or overall survival of rGBM patients.
H11: Based on IDH-1 mutation status, there is a statistically significant difference
in the time to disease progression and/or overall survival of rGBM patients.
RQ2: Is the correlation between IDH-1 mutation status and disease progression
and survival after first recurrence affected by the covariates of MGMT promoter
methylation, age, KPS, surgery for resection, and chemotherapy at progression?

57
H02 – The correlation between IDH-1 mutation status and disease progression and
survival is not affected by covariates MGMT promoter methylation, age, KPS, surgery
for resection, and chemotherapy at progression.
H12 - The correlation between IDH-1 mutation status and disease progression and
survival is affected by covariates MGMT promoter methylation, age, KPS, surgery for
resection, and chemotherapy at progression.
Table 2
Research Questions, Variables, and Statistical Methods
Research
Questions

Dependent Variable
Variable

Is there a
significant
difference in
time to disease
progression and
overall survival
after first
recurrence
between rGBM
patients with
IDH-1 mutation
and those
without IDH-1
mutation?

Time to
disease
progression or
first
recurrence
from initial
diagnosis.

Time to death
from initial
diagnosis.

Time to death
from first
recurrence.

Measurement

Independent Variables
Variable

Total number IDH-1
of days (for
mutation
each variable
listed)

Statistical
Method

Measurement
Present
(mutated
IDH-1) or
absent (wildtype IDH-1)

Cox
proportional
hazard
analysis
(hazard
ratio)

KaplanMeir Curve
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Research
Questions

Dependent Variable
Variable

Is the
correlation
between IDH-1
mutation status
and disease
progression and
survival after
first recurrence
affected by the
covariates of
MGMT
promoter
methylation,
age, KPS,
surgery for
resection, and
chemotherapy
at progression?

Time to
disease
progression or
first
recurrence
from initial
diagnosis.

Time to death
from initial
diagnosis and
first
recurrence

Measurement

Independent Variables
Variable

Total number IDH-1
of days (for
mutation
both
variables).

Statistical
Method

Measurement
Present
(mutated
IDH-1) or
absent (wildtype IDH-1)

MGMT
promoter
methylation

Methylated
or
unmethylated

Age

Years

KPS

>70 or < 70

Surgery for
resection

Yes or No

Cox
regression
analyses

Chemotherapy
at progression Yes or No

The Cox proportional-hazards model was used to assess the effect (hazard ratio)
of IDH-1 mutation status on time to disease progression and survival. In addition,
Kaplan-Meir curves were generated to obtain survival rate for patients with and without
the IDH-1 mutation. A Cox regression analysis was conducted to test the effects of key
covariates (i.e., MGMT promoter methylation, age, KPS, surgery for resection and
chemotherapy at progression) on disease progression and survival. Cox proportional
hazard model is the most commonly used statistical method in epidemiological and
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clinical studies that investigate time-to-event outcomes like death and disease
progression, which were also used in this study (Delgado et al., 2014; George et al., 2014;
Koletsi & Pandis, 2017). Similarly, the Kaplan-Meir estimation is commonly used for
survival analysis and to compare the survival distribution of two groups (George et al.,
2014). Cox proportional hazard model is also considered appropriate for time-to-event
based studies because its regression analysis allows to evaluate the independent
predictive value of selected covariates on the outcome measures like survival and time to
disease progression (Delgado et al., 2014; George et al., 2014; Koletsi & Pandis, 2017).
Since the study aimed to look at the effect of key covariates on disease progression and
overall survival in GBM patients, Cox regression analysis was considered the most
appropriate statistical method to assess the effect of selected covariates.
Research in GBM is focused on molecular, genetic, epigenetic, and
immunological markers in GBM, not only to better classify the disease but also to
evaluate the prognostic value of these markers in terms of disease outcomes (Omuro &
DeAngelis, 2013). Researchers are also evaluating the role of clinical prognostic factors,
such as age at diagnosis, tumor site, surgical resection and its timing, KPS, and
chemotherapeutic regimens, in the disease outcome. There are complex interactions
between these molecular and clinical prognostic factors and appropriate adjustments must
be made when evaluating the role of any specific factor for its prognostic value. This
study took similar considerations into account in its design. The literature review
conducted for this project suggested that MGMT promoter methylation (molecular
marker), age, KPS, surgery for resection, and chemotherapy at progression (clinical
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factors) would be important covariates when comparing the PFS and OS of rGBM
patients with and without IDH-1 mutation.
Cox proportional hazard analysis was conducted to determine the effect of IDH-1
mutation on OS and PFS utilizing the hazard ratio. Hazard ratio (HR) is used to interpret
the Cox model and it is defined as the predicted hazard function in relation to two
different conditions of a predictor variable (Delgado et al., 2014; George et al., 2014;
Koletsi & Pandis, 2017). A hazard ratio of greater than one and less than one respectively
indicates that the event is more likely or less likely to occur, whereas a HR of one
indicates that the predictor has no effect on the hazard of the event (George et al., 2014).
In this study the hazard ratio of IDH-1 mutation status on OS or PFS was determined by
this model. Cox regression analysis was also conducted to test the effects of other key
covariates on OS and PFS. Kaplan-Meir method was also used to determine the survival
rate between the IDH-1 mutated and wildtype groups.
Cox regression assumes proportional hazard and this assumption must be satisfied
to ensure proper interpretation of the data using this model (Delgado et al., 2014; George
et al., 2014; Koletsi & Pandis, 2017). While there may be a change over time in the
underlying hazard, the model assumes proportional hazards for the values of predictors,
which may be affected by time-varying covariates (George et al., 2014). Most of the
covariates selected for this study (e.g., MGMT promoter methylation status, surgery for
resection, and chemotherapy at recurrence) were categorical and did not affect the
proportional hazard assumption of the regression model. One of the covariates selected
for the study was Karnofsky Performance Score (KPS) that may change over time and
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affect the proportional hazard assumption of the regression model. Since KPS as a
covariate did not have any effect on the OS, no additional methods were used to test the
proportional hazard assumption for example, defining this covariate as a time-dependent
covariate in the SPSS and then run the Cox regression with both time-fixed and timedependent covariates (Delgado et al., 2014).
Threats to Validity
The study was designed as a retrospective cohort study based on quantitative data
collected on adult GBM patients at select hospitals in Massachusetts that is, BWH and
SVH. These hospitals were selected to make the research feasible through ease of
collaboration with oncologists at these centers and better access to EMR, which required
the researcher to go through training at these hospitals. This approach would not have
been possible if too many cancer centers had been selected, particularly in other states.
The two centers were selected to ensure appropriate representation of the population
within the state. Although no GBM patients at SVH met the inclusion criteria of having
documented recurrence and IDH-1 mutation status, the BWH database included patients
that were treated at or referred from other major hospitals in Massachusetts that is,
Massachusetts General Hospital (MGH), Beth Israel Deaconess Center (BIDC), Dana
Farber Cancer Institute (DFCI), Vermont Health Network (VHN), and Wentworth
Douglass Hospital (WDH); therefore, study sample comprised of patients from multiple
centers across the state. In addition, there is no evidence to suggest that the
pathophysiology and clinical course of GBM would be different across the United States
and the demographic information of patients in this study was consistent with the
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previously reported demographic information for GBM patients suggesting that
appropriate and representative sample of GBM was included in this study (Ostrom et al.,
2018). Furthermore, EMR provides detailed clinical data that is relevant for outcomes
research and is now increasingly used in clinical oncology and epidemiology studies (Lau
et al., 2011); therefore, the risk to external validity was considered minimal for this study.
In terms of internal validity, the study assumed that the patient data in the EMR
was collected and entered in a reliable and accurate manner, particularly for the key
variables. This assumption was appropriate considering the robust processes and standard
operating procedures that each participating hospital have in place to ensure data
integrity. It was not feasible to conduct an independent audit of the data due to hospital
policies, magnitude of the database, and patient privacy concerns under the HIPAA
(Rights (OCR), 2009). The other key assumption in context of internal validity was
regarding the clinical assessment of recurrence and disease progression in GBM patients.
While radiographic imaging was used as an objective measure to determine recurrence
and progression of disease, the assessment was still made by a clinician. GBM patients
are under the care of trained neurooncologists and such radiographical assessments are
part of regular clinical practice, including oncology.
Cohort studies may also be susceptible to selection, information, and comparison
bias and as such can affect internal validity (Euser et al., 2009). Studies that include
objective assessment of exposure and outcome adequately addresses these potential
biases. In terms of selection bias, the inclusion of the GBM subjects in the study with the
exposure of interest (IDH-1) mutation was not dependent on the likelihood of them
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having the outcome of interest (disease progression and survival). Moreover, the
diagnosis of GBM, both initial and recurring, were based on radiographic assessment and
therefore it eliminated the selection bias due to differential referral or diagnosis (Euser et
al., 2009). Similarly, information bias due to misclassification was unlikely since
presence or absence of IDH-1 mutations is made by established laboratory diagnostic
test. The use of objective measures for key independent and dependent variables also
addressed any potential concern of construct validity that requires use of correct
instruments and accurate measures of key variables (Strauss & Smith, 2009).
Considering that the prognostic value of the IDH-1 mutation for the rGBM
patients in this study was determined by comparing outcomes like time to disease
progression and mortality, the confounding variables were factored in as covariates in the
final data analysis. Cox regression analysis were conducted to address this limitation and
to evaluate the effect of these confounding variables on the outcome of interest. The
small sample size did not allow regression analysis after matching the groups for these
covariates. Inability to match groups for confounding variables is a general limitation and
challenge that researchers face when conducting research in a rare disease like GBM. In
rare diseases, the sample size is relatively small to begin with and patient heterogeneity
makes it difficult to adjust for all confounding variables while still maintaining a
reasonable sample size for statistical analysis.
Ethical Procedures
The study was conducted under the appropriate oversight of Institutional Review
Board (IRB) for human subject protection. The EMR data at BWH was accessed as part
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of an approved GBM protocol (protocol number: 2015P002352) under the supervision of
collaborating and principal investigator, Dr. Timothy Smith, Director, Computational
Neuroscience Outcomes Center and Assistant Professor of Neurosurgery, Harvard
Medical School. Similarly, approval was obtained from SVH IRB (email communication
dated July 09, 2019 – submitted to Walden University for IRB approval) to access EMR
data under the supervision of collaborating investigator Dr. Daniyal Siddiqui, Chief,
Division of Hematology and Medical Oncology. A brief outline of the proposed research
study was submitted to both collaborating oncologists and these clinicians facilitated
institutional/IRB approval. All required training at BWH was completed and this training
was also accepted by SVH prior to accessing the EMR data. Training courses for BWH
included HIPAA, Protecting Patient Privacy, and Ethical Standards along with other
general courses like Hazard Communication, Patient Care Assessment and Patient Safety.
These courses were administered by HealthStream® and a certificate was issued upon
successful completion of each course. Institutional Review Board approval was also
obtained from Walden University (approval number: 08-19-20-0036388). Confidentiality
of retrieved EMR data was maintained by ensuring that the data were not disclosed to any
unauthorized user at any time and any data that were not properly de-identified was held
with Drs. Smith and Siddiqui at the hospital with limited access by only authorized
individuals on their team. Raw data with patient identifiable information were stored with
Drs. Smith and Siddiqui at their respective hospitals and will be appropriately destroyed
after the completion of this dissertation. Further precautions were taken to safeguard
subjects’ protected health information (PHI) by de-identifying the data for confidentiality
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for example, medical record number was used for each subject included in the study
rather than the use of name or initials. De-identified data were entered in the Excel sheet
and subsequently uploaded in the SPSS software for the purposes of data analysis.
Summary
This chapter provided an overview of the methodological approach that was used
for the study. It defined the key independent variable (IDH-1) and dependent variables
(PFS and OS) that were selected for the study along with important covariates that were
considered in the data analysis. The overall study design, including study population,
sampling method, and inclusion criteria was defined in context of the overall scope of the
study. Potential threats to external and internal validity were also addressed. While the
study was conducted only at two major hospitals in Massachusetts, threat to external
validity was considered minimal because: a) the BWH database was a combined database
of BWH and MGH and included patients referred to these hospitals from other centers in
the region as well; and b) there is no evidence to suggest that the pathophysiology and
clinical course of GBM is different across the United States. Similarly, the objective
measures and assessment used for both dependent and independent variables minimized
the threat to internal and construct validity. A brief description of the statistical method
was also provided; Cox proportional hazard model and regression analysis were used to
interpret the study results and address specific research questions and hypothesis. The
results of the study are presented in Chapter 4.
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Chapter 4: Results
Introduction
The purpose of this study was to determine whether isocitrate dehydrogenase-1
(IDH-1) mutation is a prognostic factor in recurrent glioblastoma (rGBM) considering
other molecular and clinical prognostic factors as covariates. In a retrospective cohort
study, time to disease progression or death from first recurrence was evaluated in rGBM
patients with IDH-1 mutated and wild-type tumors. The effect of key variables (i.e., O6methylguanine-DNA methyl-transferase (MGMT) promoter methylation, age, Karnofsky
Performance Score (KPS), surgery and/or chemotherapy at progression) was evaluated on
the correlation between IDH-1 mutation status and disease progression and survival. The
research questions and hypothesis that this study intended to answer were:
RQ1: Is there a significant difference in time to disease progression and overall survival
after first recurrence between rGBM patients with IDH-1 mutation and those without
IDH-1 mutation?
H01: Based on IDH-1 mutation status, there is no statistically significant difference in the
time to disease progression and/or overall survival of rGBM patients.
H11: Based on IDH-1 mutation status, there is a statistically significant difference in the
time to disease progression and/or overall survival of rGBM patients.
RQ2: Is the correlation between IDH-1 mutation status and disease progression and
survival after first recurrence affected by the covariates of MGMT promoter methylation,
age, KPS, surgery for resection, and chemotherapy at progression?
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H02 – The correlation between IDH-1 mutation status and disease progression and
survival is not affected by covariates MGMT promoter methylation, age, KPS, surgery
for resection, and chemotherapy at progression.
H12 - The correlation between IDH-1 mutation status and disease progression and
survival is affected by covariates MGMT promoter methylation, age, KPS, surgery for
resection, and chemotherapy at progression.
This chapter provides an overview of how the actual data collection process went
during the research study, particularly focusing on some of the challenges and limitations
that were not anticipated prior to the start of data collection. The descriptive demographic
characteristics of the study population is also discussed along with the external validity of
the data. Data collection section is followed by detailed study results including statistical
analysis organized by research questions and hypothesis. Additional post-hoc analyses,
that were conducted based on the findings from primary analysis, are also presented in
the results section. Answers to the key research questions are then summarized at the end
of the chapter.
Data Collection
The target population consisted of adult subjects with confirmed diagnosis of
GBM and the study was based on secondary analysis through retrospective chart review
of quantitative data collected on these subjects at select hospitals in Massachusetts. Data
was collected from Electronic Medical Records (EMR) of the Brigham and Women’s
Hospital (BWH), which turned out to be a combined database of BWH and
Massachusetts General Hospital (MGH), and St. Vincent Hospital (SVH). The BWH and
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MGH database also included patients that were referred to these centers from Beth Israel
Deaconess Center (BIDC), Dana Farber Cancer Institute (DFCI), Vermont Health
Network (VHN), and Wentworth Douglass Hospital (WDH). That database was searched
for the study population and corresponding study-variables of interest during the period
of 2008 and 2020.
The major unanticipated challenge faced was that the databases were not
searchable for disease specific “key-terms” like GBM or rGBM as initially planned.
Rather, the databases could be searched only through a Research Patient Data Repository
(RPDR) query using the International Classification of Disease-10 (ICD-10) code and
GBM or rGBM does not have a specific ICD-10 code that could have been used to search
the database. Instead, ICD-10 code C71 for “malignant neoplasm of the brain” had to be
used but it includes other cancers of the brain besides GBM. As anticipated the search
based on ICD-10 code C71 resulted in approximately 1200-1500 cases that included all
neoplasms of the brain. It would not have been feasible to review individual patient
records of all these cases to identify patients that would qualify for inclusion in the study.
To make the database search manageable, the following strategy was used instead to
identify patients based on the key variables of the study that is, IDH-1 mutation status
and GBM patients with documented recurrence of their disease; therefore, the database
was first queried for all patients who had been tested for IDH-1 mutation and this search
yielded a total of 588 cases. Since IDH-1 mutation can be of interest in a variety of
oncologic conditions (e.g., myeloid leukemia, breast cancer, lung cancer, etc.) (Bledea et
al., 2019; Hodges et al., 2013), the ICD-10 code for neoplasm of the brain was then
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applied to these 588 cases to further narrow the cases to relevant study population and
this step reduced the sample size to 405 cases. In the final step, individual patient records
for all 405 cases were reviewed and per the inclusion/exclusion criteria those patients that
had non-glioblastoma tumors or GBM patients with no documented evidence of
recurrence were excluded from the dataset. This strategy resulted in a final sample size
of 177 cases, whose charts were then reviewed in detail to collect all relevant information
for detailed analyses to address the research questions. GBM is a rare disease and it was
anticipated that the overall sample size for the study is going to be small. The
inclusion/exclusion criteria of having only rGBM patients that have IDH-1 testing result,
narrowed the overall study population; however, the sample size still exceeded the
sample size of 108 that was estimated a priori using G*Power3 to detect a small effect
size at an expected power of .90 and alpha of .05 (Faul et al., 2007).
The baseline demographic characteristics of the population was not different from
the final dataset since this was a retrospective cohort study. Data on age, gender, ethnic
background was collected as part of the study and is described in the results section. The
final dataset also did not change the minimal risk to external validity that was assumed
prior to data collection. The study was initially planned based on two centers (i.e., BWH
and SVH) and while SVH did not contribute any relevant cases to the study, the database
of BWH was a combined database of BWH and MGH and this combined database also
included patients that were referred to these hospitals from other major medical
institutions and networks (i.e., BIDC, DFCI, VHN, and WDH) in Massachusetts;
therefore, the dataset provided good representation of rGBM data in Massachusetts.
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While caution needs to be taken in the generalizability of the data and results to the
broader U.S. population, there is no evidence to suggest that the pathophysiology and
clinical course of GBM would be different across the U.S.; therefore, it is anticipated that
the results of this study provide fair representation of the overall rGBM patient
population in the U.S.
The univariate analyses indicated that IDH-1 is not a prognostic factor in
recurrent GBM albeit with some data limitations. Multivariate analyses with selected
molecular and clinical covariates were conducted to complete the planned analyses and to
determine if the results were independent of other variables selected in the study. These
multivariate analyses also indicated that IDH-1 is not a prognostic factor in rGBM within
the boundaries of this study. Post-hoc analyses were conducted to evaluate the role of
IDH-1 mutation over the entire GBM disease span and to compare the results of this
study in context of the existing body of knowledge on the role of IDH-1 mutation status
in GBM and rGBM.
Results
Descriptive Statistics
This section provides: a) general information on the demographics and key
variables of the study population; and b) primary data collected on progression-free
survival (PFS) and survival to support the statistical analyses for study research
questions.
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Demographic and Key Study Variables
The general demographic information and distribution frequency of key study
variables are summarized in Table 3. The study population was predominantly White
males of 65 years or younger; the median age of the study population was 60 (25, 87)
years. Majority of patients’ tumors had wildtype IDH-1 (92%) whereas MGMT promoter
methylation status was somewhat evenly distributed between methylated (41%) and
unmethylated (51%). Clinical-based variables indicate that 60% of study population had a
KPS of >70 and patients that had surgery or received chemotherapy at recurrence were
31% and 84%, respectively. Although the patients in the database were from six different
institutions, most of the patients (88%) were treated at MGH.
Table 3
General Demographics and Key Variables
Attribute

N

Percentage

<65 years
>65 years

120
57

67.8%
32.2%

males
females

117
60

66.1%
33.9%

whites
blacks
Hispanics
Asians
American Indians
others
not provided

150
3
2
3
2
8
9

84.7%
1.7%
1.1%
1.7%
1.1%
4.5%
5.1%

wildtype
mutated
missing

163
13
1

92.1%
7.3%
0.6%

methylated

72

40.7%

Age

Gender

Race

IDH-1

MGMT
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Attribute

N

Percentage

unmethylated
missing

90
15

50.8%
8.5%

57
107
13

32.2%
60.5%
7.3%

37
81

31%
68%

102
19

84.3%
15.7%

2
156
15
2
1
1
0

1.1%
88.1%
8.5%
1.1%
0.6%
0.6%
0%

KPS
<70
>70
missing
Surgery at Recurrence
yes
no
Chemotherapy at Recurrence
yes
no
Hospitals
BWH
MGH
DFCI
BIDMC
VHN
WDH
SVH

Since IDH-1 mutation status is the key variable of the study, the distribution of
other key variables selected for the study was also assessed in context of IDH-1 mutation
status. Data tabulated for each variable in Table 4 excludes those subjects with missing
values for the stated variable. As anticipated the overall number of patients with tumors
carrying IDH-1 mutation was small (13%) with equal number of males and females and
all of these patients were <65 years. MGMT promoter methylation status was equally
distributed in the IDH-1 positive patients and most of them had either chemotherapy or
surgery at recurrence.
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Table 4
Demographic Information and Key Covariates in Context of IDH-1 Mutation Status
Variables

IDH-1 Wildtype

IDH-1 Mutated

Total

<65
>65

107 (60%)
57 (32%)

13 (7%)
0

120 (68%)
57 (32%)

male
female

110 (62%)
54 (31%)

7 (4%)
6 (3%)

117 (66%)
60 (34%)

methylated
unmethylated

64 (39%)
85 (52%)

7 (54%)
5 (38.5%)

71 (44%)
90 (56%)

<70
>70

54 (33%)
96 (59%)

3 (2%)
10 (6%)

57 (35%)
106 (65%)

yes
no

33 (28%)
78 (66%)

4 (3%)
3 (2%)

37 (31%)
81 (69%)

Chemotherapy at
recurrence
yes
no

94 (78%)
19 (16%)

7 (6%)
0

101(84%)
19 (16%)

Age

Gender

MGMT

KPS

Surgery at
recurrence

Progression-Free Survival and Overall Survival
Time in months was calculated to determine the median progression-free survival
(PFS) and median overall survival (mOS) in patients with wildtype and mutated IDH-1
gene (Table 5). PFS was defined as time from initial diagnosis to first recurrence and
time from first recurrence to subsequent recurrence. Survival was defined as time from
initial diagnosis to death and time from first recurrence to death. Data suggests that
compared to time from initial diagnosis, median PFS and OS is shorter in the recurrent
setting irrespective of IDH-1 status. Furthermore, compared to their wildtype
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counterparts, patients with IDH-1 mutation seems to have better outcomes in median PFS
and OS except for time-to-death from first recurrence.
Table 5
Median Progression Free Survival (PFS) and Overall Survival (OS)
PFS
IDH-1
Mutation
Status

OS

Initial
Diagnosis to
First
Recurrence

First
Recurrence
to Second
Recurrence

Initial
Diagnosis to
Death

First
Recurrence to
Death

Wildtype
Mdn (months)
SD
N

8
9
116

4
5
42

13
11
50

4.5
4
42

Mutated
Mdn (months)
SD
N

12
15
7

6.5
2
2

25
23
3

3
3.5
3

Statistical Analyses
Statistical analyses first focused on the specific research questions and then
additional analyses were conducted to gain an understanding of the role of IDH-1
mutation in the overall disease prognosis in GBM. Cox regression assumes proportional
hazard and this assumption must be satisfied to ensure proper interpretation of the data
using this model (Delgado et al., 2014; George et al., 2014; Koletsi & Pandis, 2017).
Almost all the variables selected for this study (i.e., IDH-1 mutation status, MGMT
promoter methylation status, surgery for resection, and chemotherapy at recurrence) are
categorical and did not affect the proportional hazard assumption of the regression model.
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Research Question 1
The first research question (RQ1) was: Is there a significant difference in time to
disease progression and overall survival after first recurrence between rGBM patients
with IDH-1 mutation and those without IDH-1 mutation? Univariate analysis of variance
(ANOVA) was conducted to evaluate the difference between the IDH-1 mutated and
wildtype groups for PFS (i.e., time from first recurrence to subsequent recurrence) and
survival (i.e., time from first recurrence to death) (Table 6). Homogeneity of variance
assumption (Levene’s test) was met for all covariates in the ANOVA. The analyses
indicated that there was no statistically significant difference in either PFS [F(1, 789.3) =
.03, p = .86] or survival [F(1, 668.6) = .04, p = .83].
Table 6
IDH-1 Mutation as Prognostic Factor in Recurrent GBM
Measure

Sum of
Squares

df

Mean
Square

F

Significance Partial Eta
Squared

PFS (first
recurrence
to second
recurrence)

789.30

1

789.30

.03

.86

.001

OS (first
recurrence
to death)

668.57

1

668.57

.04

.83

.001

Survival analysis were also conducted to test if there was a difference between the
two IDH-1 groups in terms of days from first recurrence to death. There was no
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significant difference noted in median survival times utilizing Kaplan-Meir cumulative
survival analysis (Table 7 and Figure 2) and Cox regression analysis (Table 8).
Table 7
Median Survival Time and IDH-1 Mutation Status in Recurrent GBM
Variable
IDH-1
mutation

DF

Parameter
Estimate

Standard
Error

95% CI

ChiSquare

Significance

1

181.42

18.20

64.70,
209.30

.19

.66

Figure 2
Survival Function and IDH-1 Mutation Status in Recurrent GBM
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Table 8
Cox Regression with IDH-1 Mutation Status and Survival in Recurrent GBM
Exp(B)
Variable
IDH-1
mutation

B

SE

Wald

df

(95% CI)

Significance

.26

.60

.18

1

1.3

.67

(.39, 4.24)

Since there was no statistically significant difference between IDH-1 wildtype and
mutated groups in PFS [F(1, 789.3) = .03, p = .86] and survival (HR 1.3; 95% CI, .39,
4.24; p = .67), the null hypothesis for RQ 1 was not rejected (i.e., H01: Based on IDH-1
mutation status, there is no statistically significant difference in the time to disease
progression and/or overall survival of rGBM patients).
Research Question 2
The second research question (RQ2) was: Is the correlation between IDH-1
mutation status and disease progression and survival after first recurrence affected by the
covariates of MGMT promoter methylation, age, KPS, surgery for resection, and
chemotherapy at progression. While the overall comparison of rGBM patients with IDH1wildtype and mutated genes did not indicate any difference in PFS and survival, it was
important to determine if there is an effect, or lack thereof, of selected covariates on these
outcomes. Both univariate and multivariate regression analyses was conducted evaluating
days from first recurrence to second recurrence (PFS) and first recurrence to death
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(survival) with predictors of age, gender, MGMT methylation status, KPS, and surgery or
chemotherapy at recurrence.
In terms of PFS, the univariate analysis indicated that none of the covariates had
any significant contribution to the outcome (Table 9). Similarly, there was no significant
difference in PFS when factoring in all the predictors, F(6, 198713) = 1.23, p = .31 and
none of the covariates were found to be significant contributors in PFS (Table 10).
Table 9
IDH-1 Mutation and PFS in Recurrent GBM – Effect of Covariates (Univariate Analyses)
Measure

Sum of
Squares

df

Mean
Square

F

Significance

Partial
Eta
Squared

789.30

1

789.30

.30

.86

.00

Age

40785.33

1

40785.33

1.44

.24

.03

Gender

68991.50

1

68991.50

2.50

.12

.05

MGMT
methylation

69180.32

1

69180.32

2.32

.14

.06

KPS

49151.17

49151.17

1.71

.20

.04

Surgery
and/or
chemotherapy

20463.10

20463.10

.71

.40

.02

IDH-1

1

Table 10
IDH-1 Mutation and Progression Free Survival in Recurrent GBM – Effect of Covariates
Variable
Age

B

SE

t

Significance

95% CI

52.18

61.76

.84

.40

-73.57, 177.73
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Variable

B

SE

t

Significance

95% CI

Gender

-61.52

56.94

-1.08

.29

-177.37, 54.319

MGMT
Methylation

79.77

55.02

1.45

.16

-32.15, 191.71

KPS

-66.41

61.19

-1.08

.28

-190.91, 58.08

Surgery
and/or
Chemotherapy

12.06

125.29

.09

.92

-242.86, 266.98

In terms of survival, the univariate analysis indicated that none of the covariates
had any significant contribution to the outcome (Table 11). Similar to PFS, there was no
statistically significant difference noted for survival when factoring in all the predictors,
F(6, 99178.32) = 1.17, p = .34 and none of the covariates were found to be significant
contributors in survival (Table 12).
Table 11
IDH-1 Mutation and Survival in Recurrent GBM – Effect of Covariates (Univariate
Analyses)
Measure

Sum of
Squares

df

Mean
Square

F

Significance

Partial
Eta
Squared

16086.40

1

16086.40

1.08

.30

.02

317.96

1

317.96

.02

.89

.00

MGMT
methylation

25525.80

1

25525.80

1.74

.19

.04

KPS

21341.35

1

21341.35

1.50

.23

.04

Age
Gender
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Measure

Sum of
Squares

df

Mean
Square

F

Significance

Partial
Eta
Squared

Surgery
and/or
chemotherapy

27120.25

1

27120.25

1.86

.18

.04

Table 12
IDH-1 Mutation and Survival in Recurrent GBM - Effect of Covariates
Variable

B

SE

t

Significance

95% CI

-45.69

45.50

-1.00

.32

-138.27, 46.88

Gender

3.05

43.35

.07

.94

-85.14, 91.24

MGMT
Methylation

76.36

45.59

1.67

.10

-16.39, 169.11

KPS

70.48

41.43

1.70

.10

-13.80, 154.77

Surgery
and/or
Chemotherapy

37.38

57.99

.64

.52

-80.60, 155.36

Age

The null hypothesis for RQ2 (i.e., H02 – The correlation between IDH-1 mutation
status and disease progression and survival is not affected by covariates of age, gender,
MGMT promoter methylation, KPS, surgery and/or chemotherapy at progression) was
not rejected because: a) there was no significant difference between IDH-1 wildtype and
mutated groups after factoring in covariates of age, gender, MGMT methylation status,
KPS, and surgery and/or chemotherapy at recurrence for both PFS [F(6, 198713) = 1.23,
p = .31] and survival [F(6, 99178.32) = 1.17, p = .34]; and b) none of the covariates
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showed any significant contribution to the PFS and survival after recurrence (Tables 10
and 12, respectively).
Post-hoc Analyses
Post-hoc analyses focused on evaluating the role of IDH-1 mutation in PFS and
overall survival (OS) from initial diagnosis that is, over the entire GBM disease span
rather than after recurrence, which was evaluated as part of specific research questions.
The intention was to: a) compare the data from this study with other limited studies
conducted to evaluate the role of IDH-1 in GBM; and b) assess the underlying premise of
this study that while IDH-1 mutation may be a prognostic factor in GBM if evaluated
from initial disease diagnosis, it may not be of prognostic significance once the disease
recurs or rGBM. The PFS and OS for the purposes of this post-hoc analyses was defined
as days from initial diagnosis to first recurrence and days from initial diagnosis to death,
respectively.
Univariate analysis of variance (ANOVA) was conducted to evaluate the
difference between the IDH-1 mutated and wildtype groups for PFS and OS (Table 13).
The analyses indicated that while there was no statistically significant difference in PFS
[F(1, 189074.27) = 2.26, p = .14], the difference in OS was statistically significant [F(1,
724286.53) = 5.50, p = .02].

82

Table 13
IDH-1 Mutation as Prognostic Factor in GBM
Measure

Sum of
Squares

df

Mean
Square

F

Significance Partial Eta
Squared

PFS (initial
diagnosis to
first
recurrence)

189074.27

1

189074.27

2.26

.14

.02

OS (initial
diagnosis to
death)

724286.53

1

724286.53

5.50

.02

.01

Survival analysis were also conducted to test if there was a difference between the
two IDH-1 groups in terms of days from initial diagnosis to death. There was no
significant difference noted in median survival times utilizing Kaplan-Meir cumulative
survival analysis (Table 14 and Figure 3) and Cox regression analysis (Table 15).
Table 14
Median Survival Time and IDH-1 Mutation Status in GBM
Variable
IDH-1
mutation

DF

Parameter
Estimate

Standard
Error

95% CI

ChiSquare

Significance

1

475.75

51.95

329.67,
472.33

2.12

.15
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Figure 3
Survival Function and IDH-1 Mutation Status in GBM

Table 15
Cox Regression with IDH-1 Mutation Status and Overall Survival in GBM
Exp(B)
Variable
IDH-1
mutation

B

SE

Wald

df

(95% CI)

Significance

-.86

.61

2.00

1

.423

.16

(.13, 1.40)
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Since a statistically significant difference was noted for OS (Table 13), both
univariate and multivariate regression analysis were conducted evaluating days from
initial diagnosis to death (OS) with predictors of age, gender, MGMT methylation status,
KPS, and surgery and/or chemotherapy. In the univariate analysis, gender and age were
found to be significant contributing covariates in OS and the covariate of age showed a
strong trend (Table 16). In the multivariate analysis, there was a significant difference in
OS when factoring in all the predictors, F(6, 2049021.89) = 2.48, p = .04; however, only
covariates MGMT methylation status was found to be significant contributors in OS
(Table 17).
Table 16
IDH-1 Mutation and Overall Survival in GBM – Effect of Covariates (Univariate
Analyses)
Measure

Sum of
Squares

df

Mean
Square

F

Significance

Partial
Eta
Squared

Age

393946.28

1

393946.28

2.85

.09

.05

Gender

606677.90

1

606677.90

4.53

.04

.08

MGMT
methylation

739158.35

1

739158.35

5.34

.02

.10

KPS

361769.20

1

49151.17

2.47

.12

.05

Surgery
and/or
chemotherapy

206987.90

1

206987.90

1.37

.25

.03
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Table 17
IDH-1 Mutation and Overall Survival in GBM - Effect of Covariates
Variable

B

SE

t

Significance

95% CI

Age

-141.56

142.20

-1.00

.33

-430.87, 147.74

Gender

-42.40

135.46

-.31

.76

-318.00, 233.19

MGMT
Methylation

413.90

142.47

2.90

.007

124.04, 703.77

KPS

35.27

129.47

.27

.78

-228.13, 298.67

Surgery
and/or
Chemotherapy

132.31

181.23

.73

.47

-236.40, 501.02

Based on these results, Cox regression analysis was conducted with both IDH-1
mutation and MGMT methylation status in the model considering the significant
contribution of the latter as a covariate in overall survival (Table 18). The analysis
indicated that both IDH-1 mutation and MGMT methylation were negatively correlated
with mortality and while IDH-1 mutation showed a strong statistical trend for its
contribution in OS (HR .31; 95% CI, .08, 1.12; p = .07), contribution of MGMT
methylation in OS was statistically significant (HR .38; 95% CI, .18, .80; p = .01);
however, this prognostic effect of methylated MGMT promoter was not seen following
disease recurrence in this study (HR .51; 95% CI, .23, 1.13; p = .10). The sample size of
IDH-1 mutated group was not sufficient to do further subgroup survival analysis of
MGMT methylated and unmethylated groups.
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Table 18
Cox Regression: IDH-1 Mutation and MGMT Methylation Status and Overall Survival in
GBM
Exp(B)
Variable

B

SE

Wald

df

(95% CI)

Significance

IDH-1
mutation

-1.16

.65

3.18

1

.31

.07

MGMT
methylation

-.97

(.08, 1.12)
.38

6.39

1

.38

.01

(.18, .80)

Cox regression analyses were also conducted with IDH-1 mutation and gender
and age in the model. The analysis indicated that contribution of gender was not
statistically significant in OS (HR 1.54; 95% CI, .82, 2.90; p = .18) but age was
negatively correlated with mortality and showed a strong statistical trend (HR .57; 95%
CI, .31, 1.04; p = .07) for its contribution in OS (Tables 19 and 20).
Table 19
Cox Regression: IDH-1 Mutation and Gender and Overall Survival in GBM
Exp(B)
Variable

B

SE

Wald

df

(95% CI)

Significance

IDH-1
mutation

.59

.65

.84

1

1.81

.36

Gender

.43

(.51, 6.44)
.32

1.82

1

1.54
(.82, 2.90)

.18
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Table 20
Cox Regression: IDH-1 Mutation and Age and Overall Survival in GBM
Exp(B)
Variable

B

SE

Wald

df

(95% CI)

Significance

IDH-1
mutation

.701

.619

1.28

1

2.01

.26

Age

-.56

(.60, 6.77)
.30

3.35

1

.57

.07

(.31, 1.04)

Summary
Research questions for this study aimed to assess the prognostic value of IDH-1
mutation in recurrent GBM. The following specific research questions were postulated
for the study purpose and the results related to these questions are hereby summarized:
•

The first research question was: Is there a signification difference in time to disease
progression and overall survival after first recurrence between rGBM patients with IDH-1
mutation and those without IDH-1 mutation? Time to disease progression or progression
free survival (PFS) was defined as time from first recurrence to second recurrence and
survival was defined as time from first recurrence to death. The results of the study
indicated that there was no statistically significant difference in either PFS [F(1, 789.3) =
.03, p = .86] or survival [F(1, 668.6) = .04, p = .83] of rGBM patients with IDH-1
wildtype and mutated tumors. Furthermore, survival analysis also indicated statistically
insignificant difference (HR 1.3; 95% CI, .39, 4.24; p = .67) between the two groups;
therefore, the null hypothesis of this research question was not rejected (i.e., H01: Based
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on IDH-1 mutation status, there is no statistically significant difference in the time to
disease progression and/or overall survival of rGBM patients).
•

The second research question was: Is the correlation between IDH-1 mutation status and
disease progression and survival after first recurrence affected by the covariates of
MGMT promoter methylation, age, KPS, surgery for resection, and chemotherapy at
progression. While the overall comparison of rGBM patients with IDH-1wildtype and
mutated tumors did not indicate any difference in PFS and survival, it was important to
determine if there is an effect, or lack thereof, of selected covariates on these outcomes.
The results of the study indicated that there was no significant difference in PFS [F(6,
198713) = 1.23, p = .31] and OS [F(6, 99178.32) = 1.17, p = .34] after factoring in all the
predictors and none of the covariates showed any significant contribution to either PFS or
survival after recurrence; therefore, the null hypothesis of this research question was not
rejected (i.e., H02: The correlation between IDH-1 mutation status and disease
progression and survival is not affected by covariates MGMT promoter methylation, age,
KPS, surgery for resection, and chemotherapy at progression).
The role of IDH-1 mutation as a prognostic factor in GBM remains unclear,
particularly in the recurrent disease. The results of this study, albeit with its limitations,
suggests that IDH-1 mutation is not a prognostic factor in recurrent GBM. Post-hoc
analyses conducted in this study evaluated the prognostic value of IDH-1 mutation over
the entire GBM disease span with the intention to: a) compare the data from this study
with other limited studies conducted to evaluate the role of IDH-1 in GBM; and b) assess
the underlying premise of this study that while IDH-1 mutation may be a prognostic
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factor in GBM if evaluated from initial disease diagnosis, it may not be of prognostic
significance once the disease recurs defined as rGBM. The next chapter presents the
findings of this study in context of the existing body of knowledge and interprets the
results considering the limitations of the study. The following chapter also includes
implications of this study, contribution to a positive social change in relation to clinical
practice in rGBM, and recommendations for future research.
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Chapter 5: Discussion, Conclusion, and Recommendations
Introduction
The purpose of this study was to determine whether IDH-1 mutation is a
prognostic factor in rGBM considering other molecular and clinical prognostic factors as
covariates. The prognostic value of IDH-1 mutation is debated even following initial
diagnosis of GBM since studies have demonstrated both weak and strong association
between IDH-1 mutation and overall survival (Amelot et al., 2015; Mukasa et al., 2012;
Zou et al., 2013). A few studies have examined the role of IDH-1 mutation in rGBM, but
only in the clinical trial setting and with inconclusive results (Mandel et al., 2016; Taal et
al., 2014). This study was a retrospective cohort study based on quantitative data
collected through retrospective chart reviews of adult patients diagnosed with GBM at
select hospitals in Massachusetts. Time to disease progression or death from first
recurrence was evaluated in rGBM patients with IDH-1 mutated and wild-type tumors.
The effect of key variables (i.e., MGMT promoter methylation, age, KPS, surgery for
resection, and chemotherapy at progression) was also evaluated in context of the
association between IDH-1 mutation status and disease progression and survival. The
results of this study indicated that there was no statistically significant difference in either
time to disease progression or survival of rGBM patients with IDH-1 wildtype and
mutated tumors. Similarly, the results also indicated that there was no significant
difference in time to disease progression or survival after factoring in all the predictor
variables and none of these variables showed any significant contribution to either time to
disease progression or survival after disease recurrence.
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Interpretation of the Findings
The characteristics of the study population were found to be generally consistent
with the existing knowledge on GBM. In the study database after adjusting for IDH-1
mutation, there were approximately 44% GBM patients among patients diagnosed with
neoplasm of the brain which is consistent with earlier reports that indicate that GBM
accounts for approximately 48% of all primary malignant brain tumors (Quick Brain
Tumor Facts, n.d.). The study population was predominantly White (85%) males (66%)
of 65 years or younger; the median age of the study population was 60 (25, 87) years.
These findings were consistent with previous reports that indicate a median age of 65
year at diagnosis of GBM with higher incidence in adults aged 75-85 years (Ostrom
2018). Similarly, incidence rate of GBM is considered 1.6 times higher in males and
approximately twice as greater in Whites than Blacks (Ostrom et al., 2018). Majority of
patients’ tumors in this study had wildtype IDH-1 (92%) whereas MGMT promoter
methylation status was somewhat evenly distributed between methylated (41%) and
unmethylated (51%). These results were consistent with previous reports indicating that
approximately 95% of primary GBM tumors have wildtype IDH-1 and about 50% have
methylated MGMT promoters (Lieberman, 2017; Olar & Aldape, 2014; Yang et al.,
2015).
The primary objective of this study was to determine the prognostic value of IDH1 mutation in recurrent GBM that is, progression free survival and survival following first
recurrence. The study results indicated that there was no statistically significant
difference in either PFS [F(1, 789.3) = .03, p = .86] or survival (HR 1.3; 95% CI, .39,
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4.24; p = .67) of rGBM patients with IDH-1 wildtype and mutated tumors. The results of
this study appears to be consistent with couple of studies that have examined the role of
IDH-1 mutation in rGBM, albeit in a clinical trial setting, that showed that IDH-1
mutation did not result in prolonged PFS or survival compared to IDH-1 wild-type
tumors in recurrent GBM (Mandel et al., 2016; Taal et al., 2014). While the number of
IDH-1 mutated patients in this study was approximately three times more (13 patients)
compared to the five rGBM patients with mutated IDH-1 included in the study by Mandel
(2016) and Taal (2014), analyses is still overall limited by the small number of IDH-1
mutated patients and results must be considered with caution. The results of the study
also indicated that selected predictors (i.e., MGMT promoter methylation status, age,
KPS, and surgery and/or chemotherapy at recurrence) do not affect PFS and survival
following disease recurrence. The effects of these predictors on PFS and survival have
not been studied in rGBM and multiple factors must be considered to evaluate the role of
these predictors in disease prognosis. For example, recent studies have highlighted the
timing of resection and its association with PFS and survival in GBM with a lower risk of
death noted with repeat resection without taking the timing of resection into account but a
higher risk of death was noted after adjustment for the timing of resection (Goldman et
al., 2018; Y.-H. Zhao et al., 2019). Considering the small sample size of IDH-1 mutated
group, it was not feasible to conduct further subset analyses by matching the two groups
with specific parameters for each selected covariate. Although the results of the study
indicated that the selected covariates (i.e., age, MGMT promoter methylation status,
KPS, and surgery or chemotherapy at recurrence) did not affect the PFS and survival in
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recurrent GBM, the complexity of disease pathophysiology and interactions between
molecular and clinical markers of prognosis make it challenging to conclusively
determine effect of these factors in GBM, including rGBM (Audureau et al., 2018;
Chaichana et al., 2013; Clarke et al., 2011).
The post-hoc analyses also compared the effect of IDH-1 mutation on PFS and
overall survival (OS) from initial diagnosis to first recurrence and death. The analyses
indicated that while there was no statistically significant difference in PFS [F(1,
189074.27) = 2.26, p = .14], the difference in OS was statistically significant [F(1,
724286.53) = 5.50, p = .02]. Furthermore, Cox regression analysis was conducted with
both IDH-1 mutation and MGMT methylation status in the model considering the
significant contribution of the latter as a covariate in overall survival. The analysis
indicated that both IDH-1 mutation and MGMT methylation were negatively correlated
with mortality and while IDH-1 mutation showed a strong statistical trend for its
contribution in OS (HR .31; 95% CI, .08, 1.12; p = .07), contribution of MGMT
methylation in OS was statistically significant (HR .38; 95% CI, .18, .80; p = .01). The
strong trend, but inconclusive evidence of association, noted in this study for the
prognostic value of IDH-1mutation from initial diagnosis to death seems to be reflective
of previously reported data that suggests both weak and strong association between IDH1 mutation and overall survival (Amelot et al., 2015; Chen et al., 2016; Mandel et al.,
2016; Mukasa et al., 2012; Xia et al., 2015; Zou et al., 2013). A larger sample size of
patients with IDH-1 mutation in this study may have provided a clearer perspective on
the association between IDH-1 mutation and survival following initial diagnosis. It is
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worth noting that some of the studies showing strong association between IDH-1
mutation and overall survival did not adjust for some of key contributing variables, like
MGMT promoter methylation status (Mandel et al., 2016). This study showed a
statistically significant effect of MGMT promoter methylation status on OS from initial
diagnosis and this finding is consistent with previous reports, including three metaanalysis, that have shown that OS was significantly better in patients with methylated
MGMT promoter (Olson et al., 2011; H. Zhao et al., 2016; Y.-H. Zhao et al., 2018). The
prognostic effect of methylated MGMT promoter, however, was not seen following
disease recurrence in this study. The prognostic value of methylated MGMT promoter in
rGBM has been studied in combination with other factors like radiosurgery and
researchers have suggested additional studies to specifically evaluate the role of MGMT
promoter methylation status in rGBM (Kim et al., 2017). Cox regression analysis was
also conducted with both IDH-1 mutation and age in the model considering the
significant contribution of the latter as a covariate in the univariate analysis. The median
age in the IDH-1 mutated group was 45 (35, 65) years. The analysis indicated that age
was negatively correlated with mortality and showed a strong statistical trend for its
contribution in OS (HR .57; 95% CI, .31, 1.04; p = .07). These results were consistent
with previous findings that have reported age 50 years as the typical cut-off from the
perspective of a prognostic value, with a higher risk of death seen in patients over 70
years; however, the shorter survival rate for older GBM patients is most likely due to
comorbidities and inability to tolerate the effects of the cancer itself and treatments like
surgery and chemotherapy (Ostrom et al., 2018; Thakkar et al., 2014).
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The study was aligned with the conceptual framework of outcomes research,
particularly outcomes research in oncology as proposed by Lee (2000) and generally
adopted by other researchers (Apolone, 2003; Fay et al., 2015; Kovvali, 2014; Lee et al.,
2000; Melamed et al., 2017; Roberts et al., 2019). Utilizing the outcomes measures of
PFS and survival included in the outcomes research framework, the results of this study
indicated that IDH-1 mutation was not a prognostic factor in rGBM. The results of this
study contributed to the body of knowledge on the molecular and clinical prognostic
factors that should be considered in the treatment and management of rGBM patients;
therefore, it broadly addressed both the prediction rules and the treatment options as well
as application aspect of the outcomes research framework (Lee et al., 2000).
Limitations of the Study
Even though the overall sample size of the study (177) exceeded the sample size
of 108 that was estimated a priori for statistical analyses, these analyses were limited by
the relatively small number of patients with mutated IDH-1 status (7.3%) and the results
must be interpreted with caution. An overall small sample size, including number of
patients with mutated IDH-1 status, was anticipated considering that GBM is a rare
disease, testing for IDH-1 mutation status only recently became a standard practice after
its inclusion in the classification of gliomas, and only 5% of primary GBM tumors have
mutated IDH-1 (Lieberman, 2017; Miller et al., 2017; Olar & Aldape, 2014; Ostrom et
al., 2018). These facts were evident in the data collected for this study where the original
database included about 1500 patients with neoplasm of the brain, but the final study
sample size was reduced to 177 once the key inclusion criteria were applied such as

96
documented evidence of IDH-1 mutation status and disease recurrence. The results of this
study would need to be interpreted in context of its limitations, but they could be
considered reliable since these results were overall congruent with earlier reports, as
discussed above, on the prognostic value of IDH-1 in GBM both from initial diagnosis
and following recurrence.
This study also met the parameters for external validity that were assumed prior to
data collection and analyses. The study was planned at two clinical centers in
Massachusetts, Brigham and Women’s Hospital (BWH) and St. Vincent Hospital (SVH),
to ensure appropriate representation of the population within the state. Although no GBM
patients at SVH met the inclusion criteria of having documented recurrence and IDH-1
mutation status, the BWH database included patients that were treated at or referred from
other major hospitals in Massachusetts that is, Massachusetts General Hospital (MGH),
Beth Israel Deaconess Center (BIDC), Dana Farber Cancer Institute (DFCI), Vermont
Health Network (VHN), and Wentworth Douglass Hospital (WDH). The age, gender, and
ethnic characteristics of this study population was consistent with the previously reported
demographic information for GBM suggesting that appropriate and representative sample
of GBM was included in this study. Overall, this study is considered to have good
external validity because there is no evidence to suggest that the pathophysiology and
clinical course of GBM would be different across the United States, it included patients
from multiple clinical centers across Massachusetts, and the demographic characteristics
of these patients were consistent with previously reported demographic data for GBM
(Ostrom, 2018).
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Recommendations
The primary focus of this study was to evaluate the prognostic value of IDH-1
mutation status in recurrent GBM taking into consideration other key predictors. The
limited sample size particularly for IDH-1 mutated tumors in this study underscored the
overall challenges of conducting studies in rare diseases like GBM and these challenges
are further compounded with stricter inclusion exclusion criteria typically selected to
limit the scope of the study. Following recommendations are proposed for future studies
to further confirm the findings of this study:
•

A larger study sample size to ensure that there is a higher number of patients with
mutated IDH-1 tumors in the overall study population of rGBM. Although this
retrospective study relied on a database that had patient records from major hospitals in
Massachusetts, the total number of patients with mutated IDH-1 tumors was still
relatively small (7.3%). Considering that testing for IDH-1 mutation status only recently
became a standard practice in GBM and only 5% of GBM tumors carry IDH-1 mutation,
future studies would most likely have to be conducted as multicenter studies across the
United States to increase the overall sample size thereby ensuring enough patients with
mutated IDH-1 tumors.

•

The effect of predictors like age, MGMT promoter methylations status, KPS, and surgery
or chemotherapy at recurrence on PFS and survival based on IDH-1 mutation status
should be further evaluated in rGBM. Although the results of this study indicated that
these predictors are not associated with PFS and survival based on IDH-1 mutation status,
these results cannot be considered conclusive based on the small number of IDH-1
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mutated patients; the two IDH-1 groups would have to be appropriately matched for these
predictors to provide more conclusive evidence.
•

The results of this study indicated that methylated MGMT promoter was a key predictor
of survival from initial diagnosis but not after disease recurrence. Previous studies have
mainly focused on the prognostic value of MGMT promoter methylation status in GBM
after initial diagnosis but not in recurrent GBM; therefore, future studies can further
explore the prognostic value of MGMT promoter methylation in recurrent setting to
confirm the results of this study. Recent studies have suggested that MGMT promoter
methylation status may change over time and following relapse (Feldheim et al., 2019;
Storey et al., 2019); therefore, future studies should also consider retesting of the MGMT
promoter methylation status at recurrence.

•

In this study IDH-1 mutation was negatively correlated with mortality and showed a
strong statistical trend for its contribution in overall survival from initial diagnosis (HR
.31; 95% CI, .08, 1.12; p = .07). This finding is consistent with the previous reports that
have shown both strong and weak association between IDH-1 mutation and overall
survival (Amelot et al., 2015; Chen et al., 2016; Mandel et al., 2016; Mukasa et al., 2012;
Xia et al., 2015; Zou et al., 2013). Additional studies with larger sample size are
recommended to further investigate the correlation of IDH-1 mutation and overall
survival in GBM. Consistent with previous studies, this study showed that methylated
MGMT promoter is a key prognostic factor in overall survival of GBM patients from
initial diagnosis; therefore, future studies should at least factor in MGMT promoter
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methylation status when evaluating the prognostic value of IDH-1 mutation status in
overall survival.
Implications
It is anticipated that the results of this study will bring about a positive social
change by affecting both patient treatment and health care practice in recurrent GBM.
The presumed role of IDH-1 mutation as an overall prognostic factor upon initial
diagnosis of GBM typically results in the selection of treatment modalities that are
relatively aggressive, including a combination of resection, chemotherapy, and adjuvant
therapy, with an intent to improve progression free survival and overall survival;
however, this prognostic value of IDH-1 in recurrent GBM has not been extensively
studied. The results of this study, albeit with its limitations, showed that IDH-1 mutation
is not a prognostic factor in recurrent GBM; therefore, continuation of an aggressive
treatment approach that is based on IDH-1 mutation status at initial diagnosis will most
likely not confer any clinical or survival advantage following disease recurrence.
Considering that there are significant risks associated with aggressive treatments like
chemotherapy, the results of this study may mitigate unnecessary exposure of rGBM
patients to the safety risks that are associated with treatments selected at initial diagnosis.
It is anticipated that the results of this study will also contribute to a positive social
change by informing the clinical practice guidelines to treat and manage GBM patients
following disease recurrence. It should continue to advance the conversation on how
prognostic factors like IDH-1 mutation may need to be considered differently in recurrent
setting versus initial diagnosis and patients’ quality of life and overall risks/benefits of
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treatments should be considered when selecting an optimal treatment course for patients
with recurrent GBM. Moreover, if these costly treatments that are a financial burden for
both patients and health care system are not found necessary in the recurrent disease, then
positive social change may also be affected over time through substantial savings in the
overall health care costs associated with the management of GBM and rGBM.
The results of this study underscored the relevance and utility of outcomes
research in oncology (Lee et al., 2000) and it added to the existing evidence that
prediction rules, treatment options, and application aspect of outcomes research
framework can be appropriately utilized in future studies of similar purpose and scope.
This study was designed as a retrospective cohort study based on data collected from
electronic medical records and this study design is considered relevant for outcomes
research (Lau et al., 2011). Retrospective cohort design was also selected for efficiency
because a prospective study would have been costly and time-consuming making it
impractical for this dissertation project; however, the results of this study do make a case
for prospective studies in future to further evaluate the role of prognostic factors,
including IDH-1 mutation, in recurrent GBM. The rare nature of this disease and
complex interactions between molecular and clinical prognostic factors mainly limits the
retrospective studies in terms of overall sample size, matching of the groups for
contributing variables, and occurrence of events like disease progression and death
needed for outcome analyses. Although a prospective study would take longer to
complete, it may be better suited to address research questions by mitigating some of the
limitations of retrospective study, particularly in rare diseases like GBM.
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Conclusion
Glioblastoma is an aggressive form of brain cancer that has a high recurrence rate
and very poor prognosis (Ostrom et al., 2018). The prognostic value of various molecular
markers (e.g., IDH-1 mutation, MGMT promoter methylation, etc.) and clinical factors
(e.g., age, KPS, surgery and chemotherapy, etc.) has been studied in GBM after initial
diagnosis but not as extensively in the recurrent GBM. Utilizing a retrospective cohort
design and framework of outcomes research in oncology, this study evaluated the
prognostic value of IDH-1 mutation in recurrent GBM in the context of key predictor
variables of age, MGMT promoter methylation, KPS, and surgery and chemotherapy at
recurrence. The results of this study indicated, albeit with its limitations, that IDH-1
mutation was not a prognostic factor in recurrent GBM. The prognostic value of IDH-1
mutation from initial diagnosis in this study was inconclusive consistent with previous
reports. The results of this study also indicated that although methylated MGMT
promoter was a strong prognostic factor from initial diagnosis as previously reported, it
was not a prognostic factor in recurrent GBM. Overall, the results of this study suggest
that the pathophysiology and prognosis of GBM may need to be considered differently at
initial diagnosis and following disease recurrence. Molecular markers like IDH-1
mutation and MGMT promoter methylation status are used as prognostic factors to make
treatment decisions for GBM patients at initial diagnosis. The results of this study
indicate that these molecular markers may not carry the same prognostic value after
disease recurrence and treatment decision that are made based on these markers at initial
diagnosis may not be relevant or accurate at disease recurrence. Considering that there
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are significant risks associated with aggressive treatments like combination of
chemotherapies that are selected based on prognostic factors like IDH-1 mutation and
MGMT promoter methylation at initial diagnosis, the results of this study may mitigate
unnecessary exposure of rGBM patients to the safety risks that are associated with such
treatments; therefore, it is anticipated that the results of this study will bring about a
positive social change by affecting both patient treatment and health care practice in
recurrent GBM.

103
References
Amelot, A., De Cremoux, P., Quillien, V., Polivka, M., Adle-Biassette, H., LehmannChe, J., Françoise, L., Carpentier, A. F., George, B., Mandonnet, E., & Froelich,
S. (2015). IDH-Mutation Is a Weak Predictor of Long-Term Survival in
Glioblastoma Patients. PloS One, 10(7), e0130596.
https://doi.org/10.1371/journal.pone.0130596
Apolone, G. (2003). Clinical and outcome research in oncology. The need for integration.
Health and Quality of Life Outcomes, 1, 3. https://doi.org/10.1186/1477-7525-1-3
Archavlis, E., Tselis, N., Birn, G., Ulrich, P., & Zamboglou, N. (2014). Combined
salvage therapies for recurrent glioblastoma multiforme: Evaluation of an
interdisciplinary treatment algorithm. Journal of Neuro-Oncology, 119(2), 387–
395. https://doi.org/10.1007/s11060-014-1500-8
Artene, S. A., Tuţă, C., Dragoi, A., Alexandru, O., Stefana Oana, P., Tache, D. E.,
Dănciulescu, M. M., Boldeanu, M. V., Siloşi, C. A., & Dricu, A. (2018). Current
and emerging EGFR therapies for glioblastoma. Journal of Immunoassay &
Immunochemistry, 39(1), 1–11. https://doi.org/10.1080/15321819.2017.1411816
Audureau, E., Chivet, A., Ursu, R., Corns, R., Metellus, P., Noel, G., Zouaoui, S.,
Guyotat, J., Le Reste, P.-J., Faillot, T., Litre, F., Desse, N., Petit, A., Emery, E.,
Lechapt-Zalcman, E., Peltier, J., Duntze, J., Dezamis, E., Voirin, J., … Club de
Neuro-Oncologie of the Société Française de Neurochirurgie. (2018). Prognostic
factors for survival in adult patients with recurrent glioblastoma: A decision-tree-

104
based model. Journal of Neuro-Oncology, 136(3), 565–576.
https://doi.org/10.1007/s11060-017-2685-4
Bledea, R., Vasudevaraja, V., Patel, S., Stafford, J., Serrano, J., Esposito, G., Tredwin, L.
M., Goodman, N., Kloetgen, A., Golfinos, J. G., Zagzag, D., Weigelt, B., Iafrate,
A. J., Sulman, E. P., Chi, A. S., Dogan, S., Reis-Filho, J. S., Chiang, S.,
Placantonakis, D., … Snuderl, M. (2019). Functional and topographic effects on
DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 9.
https://doi.org/10.1038/s41598-019-53262-7
Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K.
L., Patel, A. S., Rizk, E. B., Suki, D., Sawaya, R., & Glantz, M. (2016).
Association of the Extent of Resection With Survival in Glioblastoma. JAMA
Oncology, 2(11), 1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373
Calvert, A. E., Chalastanis, A., Wu, Y., Hurley, L. A., Kouri, F. M., Bi, Y., Kachman,
M., May, J. L., Bartom, E., Hua, Y., Mishra, R. K., Schiltz, G. E., Dubrovskyi, O.,
Mazar, A. P., Peter, M. E., Zheng, H., James, C. D., Burant, C. F., Chandel, N. S.,
… Stegh, A. H. (2017). Cancer-Associated IDH1 Promotes Growth and
Resistance to Targeted Therapies in the Absence of Mutation. Cell Reports, 19(9),
1858–1873. https://doi.org/10.1016/j.celrep.2017.05.014
Cancer of the Brain and Other Nervous System—Cancer Stat Facts. (n.d.). SEER.
Retrieved April 27, 2019, from https://seer.cancer.gov/statfacts/html/brain.html
Chaichana, K. L., Zadnik, P., Weingart, J. D., Olivi, A., Gallia, G. L., Blakeley, J., Lim,
M., Brem, H., & Quiñones-Hinojosa, A. (2013). Multiple resections for patients

105
with glioblastoma: Prolonging survival. Journal of Neurosurgery, 118(4), 812–
820. https://doi.org/10.3171/2012.9.JNS1277
Chen, J.-R., Yao, Y., Xu, H.-Z., & Qin, Z.-Y. (2016). Isocitrate Dehydrogenase (IDH)1/2
Mutations as Prognostic Markers in Patients With Glioblastomas. Medicine,
95(9), e2583. https://doi.org/10.1097/MD.0000000000002583
Cheng, H.-B., Yue, W., Xie, C., Zhang, R.-Y., Hu, S.-S., & Wang, Z. (2013). IDH1
mutation is associated with improved overall survival in patients with
glioblastoma: A meta-analysis. Tumour Biology: The Journal of the International
Society for Oncodevelopmental Biology and Medicine, 34(6), 3555–3559.
https://doi.org/10.1007/s13277-013-0934-5
Chin, C., Lunking, E. S., de la Fuente, M., & Ayad, N. G. (2018). Immunotherapy and
Epigenetic Pathway Modulation in Glioblastoma Multiforme. Frontiers in
Oncology, 8, 521. https://doi.org/10.3389/fonc.2018.00521
Clarke, J. L., Ennis, M. M., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F.,
Deangelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Abrey, L., Gilbert,
M. R., Mehta, M., Kuhn, J. G., Aldape, K. D., Lamborn, K. R., Prados, M. D., &
North American Brain Tumor Consortium. (2011). Is surgery at progression a
prognostic marker for improved 6-month progression-free survival or overall
survival for patients with recurrent glioblastoma? Neuro-Oncology, 13(10), 1118–
1124. https://doi.org/10.1093/neuonc/nor110

106
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014). Glioblastoma: From
molecular pathology to targeted treatment. Annual Review of Pathology, 9, 1–25.
https://doi.org/10.1146/annurev-pathol-011110-130324
Costa, B. M., Caeiro, C., Guimarães, I., Martinho, O., Jaraquemada, T., Augusto, I.,
Castro, L., Osório, L., Linhares, P., Honavar, M., Resende, M., Braga, F., Silva,
A., Pardal, F., Amorim, J., Nabiço, R., Almeida, R., Alegria, C., Pires, M., …
Reis, R. M. (2010). Prognostic value of MGMT promoter methylation in
glioblastoma patients treated with temozolomide-based chemoradiation: A
Portuguese multicentre study. Oncology Reports, 23(6), 1655–1662.
https://doi.org/10.3892/or_00000808
Czapski, B., Baluszek, S., Herold-Mende, C., & Kaminska, B. (2018). Clinical and
immunological correlates of long term survival in glioblastoma. Contemporary
Oncology (Poznan, Poland), 22(1A), 81–85.
https://doi.org/10.5114/wo.2018.73893
D’Amico, R. S., Cloney, M. B., Sonabend, A. M., Zacharia, B., Nazarian, M. N.,
Iwamoto, F. M., Sisti, M. B., Bruce, J. N., & McKhann, G. M. (2015). The Safety
of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. World
Neurosurgery, 84(4), 913–919. https://doi.org/10.1016/j.wneu.2015.05.072
Davis, M. E. (2016). Glioblastoma: Overview of Disease and Treatment. Clinical Journal
of Oncology Nursing, 20(5 Suppl), S2-8. https://doi.org/10.1188/16.CJON.S1.2-8

107
Delgado, J., Pereira, A., Villamor, N., López-Guillermo, A., & Rozman, C. (2014).
Survival analysis in hematologic malignancies: Recommendations for clinicians.
Haematologica, 99(9), 1410–1420. https://doi.org/10.3324/haematol.2013.100784
Deng, L., Xiong, P., Luo, Y., Bu, X., Qian, S., Zhong, W., & Lv, S. (2018). Association
between IDH1/2 mutations and brain glioma grade. Oncology Letters, 16(4),
5405–5409. https://doi.org/10.3892/ol.2018.9317
Euser, A. M., Zoccali, C., Jager, K. J., & Dekker, F. W. (2009). Cohort studies:
Prospective versus retrospective. Nephron. Clinical Practice, 113(3), c214-217.
https://doi.org/10.1159/000235241
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible
statistical power analysis program for the social, behavioral, and biomedical
sciences. Behavior Research Methods, 39(2), 175–191.
https://doi.org/10.3758/bf03193146
Fay, M., Head, R., & Martin, J. (2015). Where is the radiobiology and pharmacology
research to improve outcomes in glioblastoma? Journal of Neuro-Oncology,
124(1), 1–3. https://doi.org/10.1007/s11060-015-1816-z
Feldheim, J., Kessler, A. F., Monoranu, C. M., Ernestus, R.-I., Löhr, M., & Hagemann,
C. (2019). Changes of O6-Methylguanine DNA Methyltransferase (MGMT)
Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature
Review. Cancers, 11(12). https://doi.org/10.3390/cancers11121837

108
George, B., Seals, S., & Aban, I. (2014). Survival analysis and regression models.
Journal of Nuclear Cardiology: Official Publication of the American Society of
Nuclear Cardiology, 21(4), 686–694. https://doi.org/10.1007/s12350-014-9908-2
Goldman, D. A., Hovinga, K., Reiner, A. S., Esquenazi, Y., Tabar, V., & Panageas, K. S.
(2018). The relationship between repeat resection and overall survival in patients
with glioblastoma: A time-dependent analysis. Journal of Neurosurgery, 129(5),
1231–1239. https://doi.org/10.3171/2017.6.JNS17393
Golub, D., Iyengar, N., Dogra, S., Wong, T., Bready, D., Tang, K., Modrek, A. S., &
Placantonakis, D. G. (2019). Mutant Isocitrate Dehydrogenase Inhibitors as
Targeted Cancer Therapeutics. Frontiers in Oncology, 9, 417.
https://doi.org/10.3389/fonc.2019.00417
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros,
J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E. C., Hau, P.,
Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., & Stupp, R. (2005). MGMT
gene silencing and benefit from temozolomide in glioblastoma. The New England
Journal of Medicine, 352(10), 997–1003. https://doi.org/10.1056/NEJMoa043331
Hodges, T. R., Choi, B. D., Bigner, D. D., Yan, H., & Sampson, J. H. (2013). Isocitrate
dehydrogenase 1: What it means to the neurosurgeon: a review. Journal of
Neurosurgery, 118(6), 1176–1180. https://doi.org/10.3171/2013.3.JNS122282
Hsieh, F. Y., & Lavori, P. W. (2000). Sample-size calculations for the Cox proportional
hazards regression model with nonbinary covariates. Controlled Clinical Trials,
21(6), 552–560. https://doi.org/10.1016/s0197-2456(00)00104-5

109
Iwamoto, F. M., Abrey, L. E., Beal, K., Gutin, P. H., Rosenblum, M. K., Reuter, V. E.,
DeAngelis, L. M., & Lassman, A. B. (2009). Patterns of relapse and prognosis
after bevacizumab failure in recurrent glioblastoma. Neurology, 73(15), 1200–
1206. https://doi.org/10.1212/WNL.0b013e3181bc0184
Jain, K. K. (2018). A Critical Overview of Targeted Therapies for Glioblastoma.
Frontiers in Oncology, 8, 419. https://doi.org/10.3389/fonc.2018.00419
Juratli, T. A., Kirsch, M., Geiger, K., Klink, B., Leipnitz, E., Pinzer, T., Soucek, S.,
Schrock, E., Schrok, E., Schackert, G., & Krex, D. (2012). The prognostic value
of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Journal of Neuro-Oncology, 110(3), 325–333. https://doi.org/10.1007/s11060012-0977-2
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019).
Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors
Targeting Mutated IDH Proteins. Molecules (Basel, Switzerland), 24(5).
https://doi.org/10.3390/molecules24050968
Kazda, T., Dziacky, A., Burkon, P., Pospisil, P., Slavik, M., Rehak, Z., Jancalek, R.,
Slampa, P., Slaby, O., & Lakomy, R. (2018). Radiotherapy of Glioblastoma 15
Years after the Landmark Stupp’s Trial: More Controversies than Standards?
Radiology and Oncology, 52(2), 121–128. https://doi.org/10.2478/raon-20180023
Kim, B. S., Kong, D.-S., Seol, H. J., Nam, D.-H., & Lee, J.-I. (2017). MGMT promoter
methylation status as a prognostic factor for the outcome of gamma knife

110
radiosurgery for recurrent glioblastoma. Journal of Neuro-Oncology, 133(3),
615–622. https://doi.org/10.1007/s11060-017-2478-9
Koletsi, D., & Pandis, N. (2017). Survival analysis, part 3: Cox regression. American
Journal of Orthodontics and Dentofacial Orthopedics: Official Publication of the
American Association of Orthodontists, Its Constituent Societies, and the
American Board of Orthodontics, 152(5), 722–723.
https://doi.org/10.1016/j.ajodo.2017.07.009
Kovvali, G. (2014). Systems oncology: A new paradigm in cancer research. Journal of
Carcinogenesis, 13, 6. https://doi.org/10.4103/1477-3163.128641
Labussiere, M., Sanson, M., Idbaih, A., & Delattre, J.-Y. (2010). IDH1 gene mutations: A
new paradigm in glioma prognosis and therapy? The Oncologist, 15(2), 196–199.
https://doi.org/10.1634/theoncologist.2009-0218
Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F.,
DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K. L., Junck,
L., Abrey, L., Gilbert, M. R., Mehta, M., Kuhn, J. G., Aldape, K. D., Hibberts, J.,
Peterson, P. M., Prados, M. D., & North American Brain Tumor Consortium.
(2008). Progression-free survival: An important end point in evaluating therapy
for recurrent high-grade gliomas. Neuro-Oncology, 10(2), 162–170.
https://doi.org/10.1215/15228517-2007-062
Lau, E. C., Mowat, F. S., Kelsh, M. A., Legg, J. C., Engel-Nitz, N. M., Watson, H. N.,
Collins, H. L., Nordyke, R. J., & Whyte, J. L. (2011). Use of electronic medical
records (EMR) for oncology outcomes research: Assessing the comparability of

111
EMR information to patient registry and health claims data. Clinical
Epidemiology, 3, 259–272. https://doi.org/10.2147/CLEP.S23690
Lee, S. J., Earle, C. C., & Weeks, J. C. (2000). Outcomes research in oncology: History,
conceptual framework, and trends in the literature. Journal of the National
Cancer Institute, 92(3), 195–204. https://doi.org/10.1093/jnci/92.3.195
Li, R., Chen, X., You, Y., Wang, X., Liu, Y., Hu, Q., & Yan, W. (2015). Comprehensive
portrait of recurrent glioblastoma multiforme in molecular and clinical
characteristics. Oncotarget, 6(31), 30968–30974.
https://doi.org/10.18632/oncotarget.5038
Lieberman, F. (2017). Glioblastoma update: Molecular biology, diagnosis, treatment,
response assessment, and translational clinical trials. F1000Research, 6, 1892.
https://doi.org/10.12688/f1000research.11493.1
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D.,
Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W.
(2016). The 2016 World Health Organization Classification of Tumors of the
Central Nervous System: A summary. Acta Neuropathologica, 131(6), 803–820.
https://doi.org/10.1007/s00401-016-1545-1
Lu, V. M., Goyal, A., Graffeo, C. S., Perry, A., Burns, T. C., Parney, I. F., QuinonesHinojosa, A., & Chaichana, K. L. (2019). Survival Benefit of Maximal Resection
for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis. World
Neurosurgery, 127, 31–37. https://doi.org/10.1016/j.wneu.2019.03.250

112
Mandel, J. J., Cachia, D., Liu, D., Wilson, C., Aldape, K., Fuller, G., & de Groot, J. F.
(2016). Impact of IDH1 mutation status on outcome in clinical trials for recurrent
glioblastoma. Journal of Neuro-Oncology, 129(1), 147–154.
https://doi.org/10.1007/s11060-016-2157-2
Melamed, A., Rauh-Hain, J. A., & Schorge, J. O. (2017). Clinical outcomes research in
gynecologic oncology. Gynecologic Oncology, 146(3), 653–660.
https://doi.org/10.1016/j.ygyno.2017.06.016
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017). Isocitrate
dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Cancer, 123(23), 4535–4546. https://doi.org/10.1002/cncr.31039
Mohammed, S. I., Springfield, S., & Das, R. (2012). Role of epigenetics in cancer health
disparities. Methods in Molecular Biology (Clifton, N.J.), 863, 395–410.
https://doi.org/10.1007/978-1-61779-612-8_25
Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T.,
Narita, Y., Nishikawa, R., Ueki, K., & Saito, N. (2012). Significance of IDH
mutations varies with tumor histology, grade, and genetics in Japanese glioma
patients. Cancer Science, 103(3), 587–592. https://doi.org/10.1111/j.13497006.2011.02175.x
Nathan, D. G. (1998). Clinical research: Perceptions, reality, and proposed solutions.
National Institutes of Health Director’s Panel on Clinical Research. JAMA,
280(16), 1427–1431. https://doi.org/10.1001/jama.280.16.1427

113
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009). IDH1 mutations as
molecular signature and predictive factor of secondary glioblastomas. Clinical
Cancer Research: An Official Journal of the American Association for Cancer
Research, 15(19), 6002–6007. https://doi.org/10.1158/1078-0432.CCR-09-0715
Notterman, D. A., & Mitchell, C. (2015). Epigenetics and Understanding the Impact of
Social Determinants of Health. Pediatric Clinics of North America, 62(5), 1227–
1240. https://doi.org/10.1016/j.pcl.2015.05.012
Olar, A., & Aldape, K. D. (2014). Using the molecular classification of glioblastoma to
inform personalized treatment. The Journal of Pathology, 232(2), 165–177.
https://doi.org/10.1002/path.4282
Olson, R. A., Brastianos, P. K., & Palma, D. A. (2011). Prognostic and predictive value
of epigenetic silencing of MGMT in patients with high grade gliomas: A
systematic review and meta-analysis. Journal of Neuro-Oncology, 105(2), 325–
335. https://doi.org/10.1007/s11060-011-0594-5
Omuro, A., & DeAngelis, L. M. (2013). Glioblastoma and other malignant gliomas: A
clinical review. JAMA, 310(17), 1842–1850.
https://doi.org/10.1001/jama.2013.280319
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E.,
Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., Wrensch, M.
R., & Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: A
“state of the science” review. Neuro-Oncology, 16(7), 896–913.
https://doi.org/10.1093/neuonc/nou087

114
Ostrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y.,
Kruchko, C., & Barnholtz-Sloan, J. (2014). CBTRUS statistical report: Primary
brain and central nervous system tumors diagnosed in the United States in 20072011. Neuro-Oncology, 16 Suppl 4, iv1-63.
https://doi.org/10.1093/neuonc/nou223
Ostrom, Q. T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C.,
& Barnholtz-Sloan, J. S. (2017). CBTRUS Statistical Report: Primary brain and
other central nervous system tumors diagnosed in the United States in 2010-2014.
Neuro-Oncology, 19(suppl_5), v1–v88. https://doi.org/10.1093/neuonc/nox158
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J.
S. (2018). CBTRUS Statistical Report: Primary Brain and Other Central Nervous
System Tumors Diagnosed in the United States in 2011-2015. Neuro-Oncology,
20(suppl_4), iv1–iv86. https://doi.org/10.1093/neuonc/noy131
Paolillo, M., Boselli, C., & Schinelli, S. (2018). Glioblastoma under Siege: An Overview
of Current Therapeutic Strategies. Brain Sciences, 8(1).
https://doi.org/10.3390/brainsci8010015
Quick Brain Tumor Facts. (n.d.). National Brain Tumor Society. Retrieved June 9, 2020,
from https://braintumor.org/brain-tumor-information/brain-tumor-facts/
Rights (OCR), O. for C. (2009, November 20). Summary of the HIPAA Security Rule
[Text]. HHS.Gov. https://www.hhs.gov/hipaa/for-professionals/security/lawsregulations/index.html

115
Ringel, F., Pape, H., Sabel, M., Krex, D., Bock, H. C., Misch, M., Weyerbrock, A.,
Westermaier, T., Senft, C., Schucht, P., Meyer, B., Simon, M., & SN1 study
group. (2016). Clinical benefit from resection of recurrent glioblastomas: Results
of a multicenter study including 503 patients with recurrent glioblastomas
undergoing surgical resection. Neuro-Oncology, 18(1), 96–104.
https://doi.org/10.1093/neuonc/nov145
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen-Rhoades,
W., Fan, T., Khanna, C., Sweet-Cordero, E. A., Cash, T., Bishop, M. W., Hegde,
M., Sertil, A. R., Koelsche, C., Mirabello, L., Malkin, D., Sorensen, P. H.,
Meltzer, P. S., Janeway, K. A., … Crompton, B. D. (2019). Provocative questions
in osteosarcoma basic and translational biology: A report from the Children’s
Oncology Group. Cancer, 125(20), 3514–3525.
https://doi.org/10.1002/cncr.32351
Song, J. W., & Chung, K. C. (2010). Observational studies: Cohort and case-control
studies. Plastic and Reconstructive Surgery, 126(6), 2234–2242.
https://doi.org/10.1097/PRS.0b013e3181f44abc
Storey, K., Leder, K., Hawkins-Daarud, A., Swanson, K., Ahmed, A. U., Rockne, R. C.,
& Foo, J. (2019). Glioblastoma Recurrence and the Role of O6-MethylguanineDNA Methyltransferase Promoter Methylation. JCO Clinical Cancer Informatics,
3, 1–12. https://doi.org/10.1200/CCI.18.00062

116
Strauss, M. E., & Smith, G. T. (2009). Construct validity: Advances in theory and
methodology. Annual Review of Clinical Psychology, 5, 1–25.
https://doi.org/10.1146/annurev.clinpsy.032408.153639
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J. B., Janzer, R.
C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A. A.,
Gijtenbeek, J., Marosi, C., Vecht, C. J., Mokhtari, K., Wesseling, P., Villa, S.,
Eisenhauer, E., … National Cancer Institute of Canada Clinical Trials Group.
(2009). Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised phase III
study: 5-year analysis of the EORTC-NCIC trial. The Lancet. Oncology, 10(5),
459–466. https://doi.org/10.1016/S1470-2045(09)70025-7
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V.,
Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., Ram, Z., Villano, J. L.,
Rainov, N., Weinberg, U., Schiff, D., Kunschner, L., Raizer, J., Honnorat, J.,
Sloan, A., … Gutin, P. H. (2012). NovoTTF-100A versus physician’s choice
chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel
treatment modality. European Journal of Cancer (Oxford, England: 1990),
48(14), 2192–2202. https://doi.org/10.1016/j.ejca.2012.04.011
Sun, H., Yin, L., Li, S., Han, S., Song, G., Liu, N., & Yan, C. (2013). Prognostic
significance of IDH mutation in adult low-grade gliomas: A meta-analysis.
Journal of Neuro-Oncology, 113(2), 277–284. https://doi.org/10.1007/s11060013-1107-5

117
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V.,
Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F.,
Dinjens, W. N. M., Enting, R. H., Taphoorn, M. J. B., van den Berkmortel, F. W.
P. J., Jansen, R. L. H., Brandsma, D., Bromberg, J. E. C., van Heuvel, I.,
Vernhout, R. M., … van den Bent, M. J. (2014). Single-agent bevacizumab or
lomustine versus a combination of bevacizumab plus lomustine in patients with
recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. The
Lancet. Oncology, 15(9), 943–953. https://doi.org/10.1016/S14702045(14)70314-6
Tateishi, K., Wakimoto, H., & Cahill, D. P. (2017). IDH1 Mutation and World Health
Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in
Surgical Strategy. Neurosurgery, 64(CN_suppl_1), 134–138.
https://doi.org/10.1093/neuros/nyx247
Terasaki, M., Ogo, E., Fukushima, S., Sakata, K., Miyagi, N., Abe, T., & Shigemori, M.
(2007). Impact of combination therapy with repeat surgery and temozolomide for
recurrent or progressive glioblastoma multiforme: A prospective trial. Surgical
Neurology, 68(3), 250–254. https://doi.org/10.1016/j.surneu.2006.11.042
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., BarnholtzSloan, J. S., & Villano, J. L. (2014). Epidemiologic and molecular prognostic
review of glioblastoma. Cancer Epidemiology, Biomarkers & Prevention: A
Publication of the American Association for Cancer Research, Cosponsored by

118
the American Society of Preventive Oncology, 23(10), 1985–1996.
https://doi.org/10.1158/1055-9965.EPI-14-0275
Tommasini-Ghelfi, S., Murnan, K., Kouri, F. M., Mahajan, A. S., May, J. L., & Stegh, A.
H. (2019). Cancer-associated mutation and beyond: The emerging biology of
isocitrate dehydrogenases in human disease. Science Advances, 5(5), eaaw4543.
https://doi.org/10.1126/sciadv.aaw4543
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M.,
Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., Taphoorn, M. J. B., Frenay, M.,
Lacombe, D., Gorlia, T., Dinjens, W. N. M., & Kros, J. M. (2009). MGMT
promoter methylation is prognostic but not predictive for outcome to adjuvant
PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC
Brain Tumor Group Study 26951. Journal of Clinical Oncology: Official Journal
of the American Society of Clinical Oncology, 27(35), 5881–5886.
https://doi.org/10.1200/JCO.2009.24.1034
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D.,
Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M.,
O’Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S.,
Jakkula, L., … Cancer Genome Atlas Research Network. (2010). Integrated
genomic analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell,
17(1), 98–110. https://doi.org/10.1016/j.ccr.2009.12.020

119
Waitkus, M. S., Diplas, B. H., & Yan, H. (2016). Isocitrate dehydrogenase mutations in
gliomas. Neuro-Oncology, 18(1), 16–26. https://doi.org/10.1093/neuonc/nov136
WHO | The determinants of health. (n.d.). WHO. Retrieved April 27, 2019, from
https://www.who.int/hia/evidence/doh/en/
Wick, W., Osswald, M., Wick, A., & Winkler, F. (2018). Treatment of glioblastoma in
adults. Therapeutic Advances in Neurological Disorders, 11, 1756286418790452.
https://doi.org/10.1177/1756286418790452
Wilson, T. A., Karajannis, M. A., & Harter, D. H. (2014). Glioblastoma multiforme:
State of the art and future therapeutics. Surgical Neurology International, 5.
https://doi.org/10.4103/2152-7806.132138
Xavier-Magalhães, A., Nandhabalan, M., Jones, C., & Costa, B. M. (2013). Molecular
prognostic factors in glioblastoma: State of the art and future challenges. CNS
Oncology, 2(6), 495–510. https://doi.org/10.2217/cns.13.48
Xia, L., Wu, B., Fu, Z., Feng, F., Qiao, E., Li, Q., Sun, C., & Ge, M. (2015). Prognostic
role of IDH mutations in gliomas: A meta-analysis of 55 observational studies.
Oncotarget, 6(19), 17354–17365. https://doi.org/10.18632/oncotarget.4008
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I.,
Batinic-Haberle, I., Jones, S., Riggins, G. J., Friedman, H., Friedman, A.,
Reardon, D., Herndon, J., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., &
Bigner, D. D. (2009). IDH1 and IDH2 mutations in gliomas. The New England
Journal of Medicine, 360(8), 765–773. https://doi.org/10.1056/NEJMoa0808710

120
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao,
K., Li, W., Yan, W., Li, J., You, Y., Chen, C. C., & Jiang, T. (2015). IDH
mutation and MGMT promoter methylation in glioblastoma: Results of a
prospective registry. Oncotarget, 6(38), 40896–40906.
https://doi.org/10.18632/oncotarget.5683
Zang, L., Kondengaden, S. M., Che, F., Wang, L., & Heng, X. (2018). Potential
Epigenetic-Based Therapeutic Targets for Glioma. Frontiers in Molecular
Neuroscience, 11, 408. https://doi.org/10.3389/fnmol.2018.00408
Zhang, J.-L., Zhong, X.-S., Yang, S.-B., Kang, X., Li, Y., Chen, J.-X., & Li, W.-B.
(2019). Features and therapeutic potential of T-cell receptors in high-grade
glioma. Chinese Medical Journal, 132(12), 1435–1440.
https://doi.org/10.1097/CM9.0000000000000282
Zhao, H., Wang, S., Song, C., Zha, Y., & Li, L. (2016). The prognostic value of MGMT
promoter status by pyrosequencing assay for glioblastoma patients’ survival: A
meta-analysis. World Journal of Surgical Oncology, 14(1), 261.
https://doi.org/10.1186/s12957-016-1012-4
Zhao, Y.-H., Wang, Z.-F., Cao, C.-J., Weng, H., Xu, C.-S., Li, K., Li, J.-L., Lan, J., Zeng,
X.-T., & Li, Z.-Q. (2018). The Clinical Significance of O6-Methylguanine-DNA
Methyltransferase Promoter Methylation Status in Adult Patients With
Glioblastoma: A Meta-analysis. Frontiers in Neurology, 9, 127.
https://doi.org/10.3389/fneur.2018.00127

121
Zhao, Y.-H., Wang, Z.-F., Pan, Z.-Y., Péus, D., Delgado-Fernandez, J., Pallud, J., & Li,
Z.-Q. (2019). A Meta-Analysis of Survival Outcomes Following Reoperation in
Recurrent Glioblastoma: Time to Consider the Timing of Reoperation. Frontiers
in Neurology, 10, 286. https://doi.org/10.3389/fneur.2019.00286
Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., & Gu, A. (2013). IDH1/IDH2
mutations define the prognosis and molecular profiles of patients with gliomas: A
meta-analysis. PloS One, 8(7), e68782.
https://doi.org/10.1371/journal.pone.0068782

122
Appendix
Copyright Permission for Lee et al (2000, p.200)

